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Abstract 
 
Tyrosine kinases have been attracting considerable attention as target molecules for 
cancer therapy. Tyrosine kinases are enzymes which phosphorylate protein substrates, 
and they function as modulators of signal transduction pathways that induce cell 
proliferation. Tyrosine kinases can cause cancer when abnormally activated by gene 
mutations. Although various tyrosine kinase inhibitors have been created by many 
researchers and companies as drug candidates, only a few of them have been put to 
practical use in the treatment of cancer. 
One of the challenges in the successful development of a tyrosine kinase inhibitor is 
an in vivo evaluation to select promising compounds. The subcutaneous tumor-bearing 
mouse model which is often used has several problems. One of the most important of 
these problems is that the model does not always accurately reflect the pathology of 
cancer patients. In order to evaluate compounds properly, disease model animals which 
closely mimic the pathology of the specific cancer are necessary. The purpose of the 
present study was to increase the probability of selecting promising compounds in two 
projects for developing selective tyrosine kinase inhibitors as cancer therapeutics, by 
constructing appropriate disease model animals and using them to evaluate the efficacy 
of drug candidates. To this end, (1) I constructed mouse models of hematological 
malignancies (a Ba/F3 transplant model, a bone marrow transplantation model, and a 
transgenic model), and used these model mice in exploratory research on (2) dual 
BCR-ABL/ LYN tyrosine kinase inhibitors for the treatment of drug-resistant chronic 
myeloid leukemia (CML) and (3) selective JAK2 tyrosine kinase inhibitors for the 
treatment of myeloproliferative neoplasms (MPN). 
(1) I constructed a mouse model of drug-resistant CML by transplanting Ba/F3 cell 
lines which had been retrovirally transduced with the causative genes (mutated 
BCR-ABL genes). These mice exhibited the pathology of leukemia in a short period of 
time, and were resistant to existing drug (Ba/F3 transplant model). Similarly, I 
constructed a mouse model of MPN by transplanting donor bone marrow cells 
retrovirally transduced with the causative mutated JAK2 genes (bone marrow transplant 
model). I also adopted transgenic mice which expressed mutated JAK2 under the 
control of the H2Kb promoter, as an animal model that reproduced the characteristic 
pathology of MPN (transgenic model). (2) A group of compounds including NS-187 has 
been found as a result of screening for dual BCR-ABL/ LYN tyrosine kinase inhibitors. I 
demonstrated that NS-187 substantially prolonged survival in Ba/F3 transplant model 
 2 
 
mice. (3) A group of compounds including NS-018 was discovered by screening for 
potent and selective JAK2 inhibitors. I conducted repeat-dose tests of NS-018 in bone 
marrow transplant and transgenic model mice, and demonstrated that NS-018 had good 
efficacy with reduced hematological adverse effects. 
In this study, I constructed animal models that accurately reflected patient pathology 
in two types of hematological malignancies that could not be reproduced in conventional 
models. As a result of improved screening of tyrosine kinase inhibitors using these 
animal models, it was possible to increase the probability of selecting promising 
compounds. The compounds selected, NS-187 and NS-018, are in clinical trial for the 
treatment of CML and MPN, respectively. 
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Chapter 1 
 
General introduction 
 
1-1 Molecularly targeted anticancer drugs 
 
1-1-1 History of cancer research 
 
Cancer research has a history of over 2000 years [1]. The ancient Greek physician 
Hippocrates, the “Father of Medicine”, described several kinds of cancer. He named it 
“cancer”, meaning crab or crayfish. In ancient Rome, Galen proposed that cancer 
occurred because of an imbalance in the four basic body fluids (Humorism). His 
theories dominated and influenced medical science in the Western and Islamic worlds 
for more than 1300 years. During the Renaissance, scientists developed a greater 
understanding of the human body and disease. Followers of René Descartes believed 
that all disease was the outcome of chemical processes, and that acidic lymph fluid was 
the cause of cancer (Lymph theory). In the 19th century, Johannes Müller demonstrated 
that cancer tissue was made of cells and not lymph, and proposed that cancer cells 
developed from budding elements between normal tissues (Blastema theory). His 
student Rudolph Virchow proposed that chronic irritation was the cause of cancer 
(Chronic irritation theory). Throughout the 17th and 18th centuries, some scientists 
believed that cancer was contagious (Infectious disease theory). In the 18th century, 
John Hill recognized tobacco as a substance that caused cancer (chemical carcinogen), 
while in 1911 Peyton Rous showed that certain viruses can increase the risk of 
developing cancer (viral carcinogen). The genetic basis of cancer was recognized by 
Theodor Boveri in 1902. He suggested that mutations of chromosomes could generate 
a cell with unlimited growth potential which could be passed on to its descendants 
(Chromosome theory). 
Today scientists know that cancer is fundamentally a disease involving failure of the 
regulation of tissue growth. It usually results from changes in genetic or epigenetic 
factors, which could be caused by chemicals, radiation, or viruses, although there is a 
hereditary component to some cancers. However, the mechanisms of cancer 
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development have not been completely elucidated, and different researchers have 
different views on the mechanisms involved. The mainstream theory is that the degree 
of malignancy increases with the accumulation of genetic abnormalities within a cell 
(Multistep carcinogenesis). Some researchers have proposed that the different kinds of 
cells in a heterogeneous tumor arise from a single cell, which retains key stem cell 
properties (Cancer stem cell hypothesis). They advocate that the relapse of cancer and 
the emergence of metastasis are also attributable to cancer stem cells. There are many 
other concepts and ideas on oncogenesis. As described later, this thesis addresses the 
theme of molecularly targeted anticancer drugs, and employs a hypothesis called 
“driver mutation“ or “oncogene addiction” [2], which provides a rationale for molecularly 
targeted therapy. 
 
1-1-2 Cancer epidemiology and treatment 
 
The worldwide cancer patient population continues to grow. In Japan, the number of 
cancer cases in 2007 was approximately 704000, and the number of cancer deaths in 
2011 was approximately 357000 [3]. It is estimated that one in two Japanese are 
diagnosed with cancer during their lifetime, and that one in four Japanese males and 
one in six Japanese females die from cancer. The incidence of cancer is expected to 
further increase in step with the aging of the population (Figure 1-1) [4]. 
 
Figure 1-1.  Incidence of cancer in Japan. 
The crude incidence rate of cancer has been continuously increasing for both 
sexes since the 1980’s. 
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The main treatments for cancer include surgery, radiation therapy, and chemotherapy. 
In many types of cancer, including advanced-stage carcinomas and hematological 
malignancies, surgery and radiation therapy are not feasible. In such cases, 
chemotherapy with anticancer drugs is used. Although the treatment outcome of 
chemotherapy has improved, many patients still have recurrences of cancer. 
Furthermore, because most conventional anticancer drugs are cytotoxic not only to 
cancer cells but also to normal cells, side effects are inevitable. Cancer treatments with 
fewer side effects and a lower risk of cancer relapse are highly desirable. 
 
1-1-3 Molecularly targeted anticancer drugs 
 
Molecularly targeted anticancer drugs block a specific target molecule which is 
expressed specifically or excessively and is needed for the growth of the cancer cells. 
Molecularly targeted anticancer drugs differ from conventional anticancer drugs in 
several ways. Thus, molecularly targeted anticancer drugs act on specific molecular 
targets that are associated with cancer, whereas most conventional chemotherapeutic 
agents act on all rapidly dividing cells, both normal and cancer cells. In addition, 
molecularly targeted anticancer drugs are deliberately chosen or designed to interact 
with their target, whereas many conventional anticancer drugs were identified by their 
ability to kill cells. In principle, molecularly targeted anticancer drugs are expected to be 
more effective than conventional chemotherapeutic agents and less harmful to normal 
cells. 
Molecularly targeted anticancer drugs include monoclonal antibodies and 
small-molecule inhibitors. Monoclonal antibodies are a good approach for targeting 
extracellular/cell surface molecules. On the other hand, small-molecule inhibitors have 
the advantages that they can be targeted to intracellular molecules and administered 
orally. This thesis concerns small-molecule inhibitors. Small-molecule compounds often 
inhibit non-target molecules as well as the target molecule, leading to unexpected 
adverse effects. Therefore, to increase the effectiveness of small-molecule compounds 
and decrease their side effects, rational drug design to increase target selectivity is 
important. 
It is difficult to select an appropriate target molecule for a molecularly targeted 
anticancer drug. There are a lot of signaling pathways involved in the growth of cancer 
cells (Figure 1-2) [5]. Even if one pathway is inhibited, cancer cells can often survive by 
using other pathways. However, the inhibition of many pathways will increase not only 
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the efficacy but also the likelihood of adverse effects. Although the inhibition of a limited 
number of pathways is possible, it is unrealistic to try all combinations of a few pathways 
because of the large number of combinations. Recent studies indicate that there is a 
singular solution to certain types of cancer. The survival and proliferation of some 
cancer cells are almost completely dependent on a few pathways downstream of the 
mutated molecule (oncogene addiction) [2,6]. In this specific case, complete inhibition of 
the mutated molecule can eliminate the cancer cells. Mutated tyrosine kinases in certain 
types of hematological malignancy are such candidate target molecules. 
 
 
 
Figure 1-2.  Signaling pathways in cancer. 
During oncogenesis, gene mutations or expression changes accumulate in 
biological pathways such as those involved in the cell cycle, apoptosis, DNA 
damage repair, growth factor responses, cell adhesion, and angiogenesis. 
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1-2 Tyrosine kinase inhibitors 
 
1-2-1 Function and categories of kinases 
 
Kinases are enzymes that transfer phosphate groups from ATP to specific substrates, 
a process referred to as phosphorylation. Kinases function as regulators (on/off 
switches) of metabolic and signal-transduction pathways in cells. 
Kinases are broadly classified into two types: (1) those that act on 
low-molecular-weight substrates in mainly metabolic pathways (e.g., creatine kinase, 
pyruvate kinase, hexokinase), and (2) those that act on protein substrates in 
intracellular signal-transduction pathways (protein kinases). This thesis concerns 
protein kinases. Eukaryotic protein kinases include tyrosine kinases and 
serine/threonine kinases, which phosphorylate the hydroxyl group of tyrosine residues 
or serine/threonine residues, respectively, of various proteins. There are at least 518 
protein kinases in the human genome, and they are classified into nine groups by 
sequence homology (Figure 1-3) [7]. Of these protein kinases, 90 are tyrosine kinases, 
and the rest are serine/threonine kinases. Tyrosine kinases can be further divided into 
receptor tyrosine kinases and non-receptor tyrosine kinases. JAK-family and 
SRC-family kinases and ABL kinase, covered in this thesis, are non-receptor tyrosine 
kinases. 
More than 99% of amino acids phosphorylated by kinases are serine/threonine, and 
the phosphorylated tyrosines represent less than 0.1%. However, the quantitatively less 
important phosphorylation of tyrosine plays an important physiological role. Tyrosine 
kinases function as regulators of signaling involved in cell differentiation, proliferation, 
adhesion, and immune reactions. Binding of growth factors and cytokines, such as 
insulin and interferon, to their receptors is converted to intracellular signals by tyrosine 
kinases. The phosphorylated protein changes its structure and relays signals 
downstream. 
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Figure 1-3.  Phylogenetic tree of kinase family. 
Human protein kinases are classified into nine major groups, and are 
subdivided into families, and sometimes subfamilies, based on the sequence of 
their kinase domains. Illustration reproduced courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com). 
 
1-2-2 Structure and activation of kinases 
 
Although most protein kinases contain multiple domains, the kinase activity is 
associated with a kinase domain, which is highly conserved. The kinase domain can be 
SRC-family
JAK-family
ABL
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divided into subdomains: the N-terminal lobe, the C-terminal lobe, and the hinge region 
connecting them (Figure 1-4) [8]. The N-terminal lobe is mainly involved in the binding 
and placement of ATP via the phosphate-binding loop (P-loop). The C-terminal lobe is 
involved in the recognition and binding of the substrate protein and in part ATP-binding 
via the activation loop (A-loop), which changes its conformation greatly by 
phosphorylation. In the C-terminal lobe, there is a catalytic loop (C-loop) which contains 
an aspartic acid residue as the catalytic base in the phosphorylation reaction. A deep 
cleft between the two lobes is the active center, in which the binding of ATP and the 
protein substrate occur. 
 
 
Figure 1-4.  Structure of the kinase domain. 
Left: Off (inactive) state of ABL. Right: On (activated) state of ABL. The 
activation loop (A-loop) is shown in pink. Protein Data bank IDs are 1IEP and 
2GQG. 
 
Kinase activation is highly regulated, and the kinase itself is turned on or off by 
phosphorylation. In the off (inactive) state, A-loop is folded and blocks the cleft between 
the lobes so that ATP cannot reach the catalytic center of the kinase. When it is 
converted to the on (activated) state by phosphorylation (sometimes by another kinase 
and sometimes by the kinase itself; cis-phosphorylation/autophosphorylation), the 
phosphorylated A-loop moves away from the cleft, and ATP and the substrate protein 
can reach the binding site in the active center. 
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1-2-3 Tyrosine kinase mutations in hematological malignancy 
 
Kinase activation is usually tightly controlled, but kinases can be activated 
constitutively by gene mutations. The aberrant activation of kinases by mutations has 
been reported in some types of cancer, including hematological malignancies. 
For example, BCR-ABL is an abnormal fusion kinase detected in virtually all patients 
with chronic myeloid leukemia (CML) [9]. As a result of chromosomal translocation, part 
of the BCR gene from chromosome 22 is fused with the ABL gene on chromosome 9 
(Figure 1-5). Because ABL is a tyrosine kinase, the BCR-ABL fusion gene product is 
also a tyrosine kinase. The kinase domain of normal ABL tyrosine kinase is negatively 
regulated by the SH3 domain and does not show activity. However, in BCR-ABL kinase 
the suppressive function is released by the formation of a tetramer around the 
N-terminal portion of BCR. As a result of intermolecular phosphorylation, BCR-ABL 
kinase is constitutively active. BCR-ABL tyrosine kinase promotes aberrant cell growth 
and anti-apoptotic signaling mainly by activating the RAS, PI3K/AKT, and STAT 
pathways. Thus, BCR-ABL fusion is a driver mutation that gives a selective advantage 
to a clone cell and causes clonal expansions in CML. 
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Figure 1-5.  BCR-ABL tyrosine kinase in chronic myeloid leukemia. 
The reciprocal translocation between the chromosomes 9 and 22 results in the 
generation of the abnormal tyrosine kinase BCR-ABL, which causes 
unregulated cell proliferation and malignant alteration. 
 
Another example of the aberrant activation of a kinase by a mutation is a mutation of 
JAK2 tyrosine kinase observed in patients with myeloproliferative neoplasms (MPN) 
[10]. JAK2 tyrosine kinase has seven JH (Janus homology) domains (Figure 1-6). The 
JH1 domain at the C-terminal site has kinase activity. The JH2 domain is a 
pseudokinase domain that does not have kinase activity. JAK2 kinase is usually 
maintained in an inactive state by interaction of the JH1 and JH2 domains. A point 
mutation (V617F) in the JH2 domain suppresses the interaction with JH1, leading to 
constitutive JAK2 kinase activity. Mutated JAK2 tyrosine kinase promotes aberrant cell 
growth and anti-apoptotic signaling, mainly by activating the STAT, RAS/MAPK, and 
PI3K/AKT pathways. Thus, JAK2 V617F is a driver mutation in MPN. 
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Figure 1-6.  Mutation of JAK2 tyrosine kinase in myeloproliferative 
neoplasms. 
A somatic point mutation in the JAK2 gene causes constitutive activation of the 
tyrosine kinase, which dysregulates cell growth and function. 
 
1-2-4 Tyrosine kinase inhibitors 
 
Because targeting the abnormally activated tyrosine kinase in cancer cells can be 
expected to suppress abnormal growth and induce apoptosis, tyrosine kinase inhibitors 
have been developed by many researchers and companies. Although kinase inhibitors 
have been studied since the early 1980's, the impetus for their development as drug 
candidates was the report about the kinase inhibitory effect of staurosporine in 1986 [11]. 
However, because staurosporine inhibits many kinases and shows little selectivity, 
clinical application of staurosporine was not possible in view of its side effects. For 
safety and high efficacy, excellent selectivity for the target kinase is required. The first 
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tyrosine kinase inhibitor put to practical use was imatinib mesylate (trade name, 
Gleevec), a selective ABL tyrosine kinase inhibitor [12]. As described in Chapter 2, 
imatinib showed excellent efficacy and safety in CML patients and became a 
breakthrough drug that drastically changed the treatment of CML. 
More than 200 tyrosine kinase inhibitors are currently in clinical trials worldwide 
(Figure 1-7). To be approved as a therapeutic agent, a drug candidate must clear a 
number of hurdles such as efficacy, safety, pharmacokinetics, and physical properties. 
To date, only 13 tyrosine kinase inhibitors have been approved for the treatment of 
cancer. Many tyrosine kinase inhibitors have not shown a sufficient therapeutic effect in 
patients. 
 
Figure 1-7.  Molecularly targeted anticancer drugs in clinical trial. 
Monoclonal antibodies, protein drugs, nucleic acid medicines, vitamin A 
derivatives, endocrine therapy agents, and thalidomide-based drugs are 
excluded. Abbreviation: Ser/Thr, serine/threonine. 
 
 
1-3 The drug discovery process 
 
The drug discovery process for molecularly targeted anticancer drugs is still in need 
of improvement, and there are many challenges. Figure 1-8 shows a simplified view of 
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and screening evaluations are repeated to increase the activity and selectivity of the 
compounds, and a relatively small number of which are selected. Finally, after 
evaluations such as in vivo efficacy, pharmacokinetics, and safety, one candidate is 
selected for clinical trial. However, as described in the previous section, a significant 
number of tyrosine kinase inhibitors in the pipeline have not shown a sufficient 
therapeutic effect in patients. 
One of the most difficult parts of the drug discovery process is in vivo evaluation to 
select promising compounds [13]. In many cases, tumor-bearing model animals are 
used to evaluate the efficacy of compounds from point of the view of a high throughput 
(high numbers, short times, and convenience). In particular, cancer cell lines are often 
implanted subcutaneously into the backs of mice. However, there are several problems 
with this model [14,15]. Such model animals do not necessarily reflect the pathology of 
cancer patients accurately. The only outcome measure evaluated is tumor volume. In 
addition, the site of action of the drug is often different from the location of the original 
cancer. Compounds which decrease tumor volume in inappropriate model animals do 
not necessarily improve the clinical condition of patients. In order to evaluate 
compounds properly, it is necessary to use disease model animals which closely reflect 
the pathology of the cancer under study. 
 
 
Figure 1-8.  Drug discovery process for molecularly targeted anticancer 
drugs. 
Once a target molecule is decided upon, various screening assays for 
promising compounds are done to evaluate their efficacy, metabolism, and 
safety. 
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1-4 Purpose of the work described in this thesis 
 
The purpose of the study is to increase the probability of selecting promising 
compounds in two projects for developing selective tyrosine kinase inhibitors as cancer 
therapeutics, by constructing the appropriate disease model animals and performing the 
efficacy evaluation in these models. To this end, I introduced three mouse models of 
hematological malignancy (a Ba/F3 transplant model, a bone marrow transplantation 
model, and a transgenic model) for the screening processes. Specifically, I applied 
these model mice to exploratory research on dual BCR-ABL/LYN tyrosine kinase 
inhibitors for the treatment of drug-resistant CML (Chapters 2 and 3) and to research on 
selective JAK2 tyrosine kinase inhibitors for the treatment of MPN (Chapters 4 and 5) 
and myelodysplastic syndromes (Chapter 6). 
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Chapter 2 
 
Discovery and characterization of a selective 
Bcr-Abl/Lyn tyrosine kinase inhibitor, NS-187, for 
the treatment of imatinib-resistant chronic 
myeloid leukemia 
 
 
2-1 Introduction 
 
The Philadelphia (Ph) chromosome results from a reciprocal translocation between 
chromosomes 9 and 22 that generates the breakpoint cluster region–Abelson (Bcr-Abl) 
chimeric protein, which in turn causes chronic myeloid leukemia (CML) and Ph+ acute 
lymphoblastic leukemia (ALL) [16,17]. Imatinib mesylate (STI571, Gleevec) specifically 
inhibits the autophosphorylation of Abl tyrosine kinase and is not only highly efficacious 
in treating these diseases but also generally produces only mild side effects [18]. Within 
a few years of its introduction to the clinic, imatinib dramatically altered the first-line 
therapy for CML [19]. Most newly diagnosed CML patients in the chronic phase achieve 
durable responses when treated with imatinib [19]. However, a small percentage of 
these patients as well as most advanced-phase patients relapse on imatinib therapy 
[20,21]. Bcr-Abl–dependent mechanisms of resistance to imatinib include 
overexpression of Bcr-Abl and amplification of the bcr-abl gene and, most intriguingly, 
point mutations within the Abl kinase domain that interfere with imatinib binding [22-25]. 
To overcome imatinib resistance, higher doses of imatinib and combination therapy 
with other agents have been used with some efficacy. However, these strategies are 
limited in their application and effectiveness, especially for patients with Abl point 
mutations [26-28]. Therefore it is necessary to develop more effective Abl tyrosine 
kinase inhibitors. Several Src inhibitors from various chemical classes, including 
PD166326 [29], SKI-606 [30], AP23464 [31], and BMS-354825 [32], have been found to 
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be 100 to 300 times more effective than imatinib in blocking Bcr-Abl tyrosine kinase 
autophosphorylation, and these effects extend to point mutants of Bcr-Abl. However, 
while imatinib binds to only the inactive form of Abl, these dual Src-Abl inhibitors also 
bind to the active form, which shares considerable conformational similarity with the 
active forms of diverse tyrosine kinases, including the Src-family proteins [31,33]. This 
characteristic of dual Src-Abl inhibitors has some advantage with respect to Lyn kinase, 
a Src-family protein, because overexpression of Lyn is associated with imatinib 
resistance [34-36]. It has been shown that dual Src-Abl inhibitors can simultaneously 
inhibit Lyn [33] and this may enhance their ability to induce apoptosis in CML cells. 
However, the effect of lower specificity against Src-family kinases is not yet fully 
understood because these kinases play many important roles in vivo [37-41]. 
 Thus we sought to identify a novel orally bioavailable compound for treating Ph+ 
leukemias that (1) is more potent than imatinib in blocking Bcr-Abl kinase activity, 
including variants with point mutations in the kinase domain; (2) has fewer adverse 
effects; and (3) inhibits Lyn while otherwise remaining highly specific for Bcr-Abl. The 
crystal structure of the Abl kinase domain in complex with imatinib shows that some 
alterations to the structure of the drug are likely to be tolerated [42,43]. Chemical 
modifications made with the guidance of molecular modeling yielded several promising 
compounds. Among them, a potent and specific dual Abl-Lyn inhibitor, NS-187 (Figure 
2-1A), was selected on the basis of its overall characteristics, including its 
pharmacokinetics and toxicity as determined in animal studies. NS-187 was found to be 
much more effective than imatinib and to inhibit Lyn at clinically relevant concentrations 
without affecting the phosphorylation of Src, Blk, or Yes. Its inhibitory effect extended to 
almost all Bcr-Abl point mutants tested. 
 
 
2-2 Materials and Methods 
 
2-2-1 Reagents and cell lines 
 
NS-187 and imatinib were synthesized and purified at Nippon Shinyaku (Kyoto, 
Japan). The compounds were dissolved as 10 mM aliquots in dimethyl sulfoxide 
(Sigma-Aldrich, St Louis, MO) and stored at -80°C until required for use. K562 (chronic 
myeloid leukemia), U937 (histiocytic lymphoma), NCI-H526 (small cell lung cancer), and 
A431 (epidermoid carcinoma) cells were obtained from the American Type Culture 
Collection (Manassas, VA). KU812 (chronic myeloid leukemia) and NHDF (normal 
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fibroblast) cells were obtained from the Japanese Collection of Research Biosources 
(Osaka, Japan) and Kurabo (Osaka, Japan), respectively. Ba/F3-wt, Ba/F3-E255K, and 
Ba/F3-T315I cells were kindly provided by Dr Martin Ruthardt of Frankfurt University. 
K562, KU812, U937, Ba/F3-wt, Ba/F3-E255K, and Ba/F3-T315I cells were cultured in 
RPMI-1640 (Nissui, Tokyo, Japan) with 2 mM L-glutamine (Nacalai Tesque, Kyoto, 
Japan) and 10% fetal bovine serum (FBS; Vitromex, Vilshofen, Germany). NCI-H526 
cells were cultured in RPMI-1640 with 2 mM L-glutamine, 4.5 g/L glucose (Nacalai 
Tesque), 10 mM HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid; 
Sigma-Aldrich), 1.0 mM sodium pyruvate (ICN Pharmaceuticals, Costa Mesa, CA), and 
10% FBS. A431 and NHDF cells were cultured in Dulbecco modified Eagle medium 
(DMEM; Nissui) with 4 mM L-glutamine and 10% FBS. All cell lines were maintained at 
37°C in a fully humidified atmosphere of 5% CO2. Cells undergoing exponential growth 
were used in the experiments. 
 
2-2-2  Generation and purification of Abl kinase domains 
 
The Abl kinase domain, which consists of c-Abl amino acids 229-515, was amplified 
by polymerase chain reaction with K562 cDNA as a template and subcloned into the 
pENTR/D-TOPO vector (Invitrogen, Carlsbad, CA). Each mutation (E244V, G250E, 
Q252H, Y253F, E255K, E255V, T315I, F317L, M351T, E355G, F359V, H396P, and 
F486S) was introduced by using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). The presence of the mutations was confirmed by 
sequencing. The wild-type (wt) and mutated kinase domains in the pENTR/D-TOPO 
vector were transferred to the pDEST10 vector (Invitrogen) by recombination with 
Gateway LR clonase (Invitrogen). Sf9 cells were infected with baculovirus generated 
from each kinase domain pDEST10 by using the Bac-to-Bac Baculovirus Expression 
System (Invitrogen). After inoculation, Sf9 cells were lysed and the kinase domain was 
purified on a Q-Sepharose Fast Flow anion-exchange column (Amersham Biosciences, 
Piscataway, NJ) and a HisTrap HP column (Amersham Biosciences). The protein 
concentration of each kinase domain was determined by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) followed by staining with 
Coomassie Brilliant Blue. 
 
2-2-3  Kinase assay 
 
Bcr-Abl kinase assays were performed in 25 μL of reaction mixture containing 250 μM 
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peptide substrate, 740 Bq/μL [γ-33P]ATP, and 20 μM cold adenosine triphosphate (ATP) 
by using the SignaTECT protein tyrosine kinase assay system (Promega, Madison, WI). 
Each Bcr-Abl kinase was used at a concentration of 10 nM. Kinase assays for Abl, Src, 
and Lyn were carried out with an enzyme-linked immunosorbent assay (ELISA) kit from 
Carna Biosciences (Kobe, Japan). The inhibitory effects of NS-187 against 79 tyrosine 
kinases were tested with KinaseProfiler (Upstate, Dundee, United Kingdom). 
 
2-2-4 Inhibition of intracellular tyrosine kinases 
 
K562 cells, BaF3/wt cells, BaF3/E255K cells, and BaF3/T315I cells were treated with 
serial dilutions of the compounds for 1.5 hours. Serum-starved NHDF cells, NCI-H526 
cells, and A431 cells were treated with serial dilutions of the compounds for 1.5 hours 
followed by stimulation with 50 ng/mL platelet-derived growth factor (PDGF; Upstate), 
100 ng/mL stemcell factor (SCF; R&D Systems, Minneapolis, MN), or 100 ng/mL 
epidermal growth factor (EGF; R&D Systems) for 10 minutes. Cells were harvested and 
lysed with radioimmunoprecipitation assay (RIPA) buffer, and equal amounts of cell 
lysate protein were analyzed by Western blotting with antiphosphotyrosine antibody 
PY20 conjugated with horseradish peroxidase (BD Transduction Laboratories, San 
Jose, CA) and anti–c-Abl antibody, anti–c-Kit antibody, anti–CT10 regulator of kinaselike 
(anti-CrkL) antibody, anti–EGF receptor (anti-EGFR) antibody, anti–extracellular 
signal-related kinase 1 (anti-ERK1) antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA), or anti-PDGFR type A/B (Upstate). 
 
2-2-5 Cell proliferation assays 
 
K562, BaF3/wt, BaF3/E255K, and BaF3/T315I cells were plated in triplicate at 1 x 103 
cells/well in 96-well plates, whereas KU812 and U937 cells were plated in triplicate at 5 
x 103 cells/well in 96-well plates. Cells were incubated with serial dilutions of the 
compounds for 3 days. Cell proliferation was measured by MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Nacalai Tesque) assay, 
and the 50% inhibitory concentration (IC50) values were calculated by fitting the data to 
a logistic curve. 
 
2-2-6 Subcutaneous xenograft model and BaF3 leukemia models 
 
Approvals for the following in vivo studies were obtained from the institutional review 
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board at Kyoto University Hospital. Balb/c-nu/nu female mice 8 weeks of age were 
purchased from Japan Clea (Osaka, Japan). KU812 xenograft was established by 
subcutaneous injection of 2.5 x 107 cells into the right flank of the mice. Seven days 
after inoculation, the mice were randomized into groups of 5, and NS-187, imatinib, or 
vehicle (0.5% methylcellulose) was administered orally twice a day by gavage for 10 
consecutive days. Tumor sizes were assessed at least twice a week by caliper 
measurement and their volumes calculated from the formula, tumor size (cm3) = (d2 x 
D)/2/1000, where d and D are the shortest and longest diameter of the tumor, 
respectively. Significant differences between samples were determined with the Dunntt 
test. 
  Ba/F3-wt leukemia was established by intravenous injection of 1 x 106 cells into the 
tail vein of Balb/c-nu/nu mice. The next day the mice were randomized into groups of 7, 
and NS-187, imatinib, or vehicle (0.5% methylcellulose) was administered orally twice a 
day for 11 consecutive days. Ba/F3-E255K leukemia was established by intravenous 
injection of 5 x 104 cells into the tail vein of Balb/c mice. The next day the mice were 
randomized into groups of 3, and NS-187, imatinib, or vehicle was administered orally 
twice a day for 26 consecutive days. Survival analysis was performed by the 
Kaplan-Meier method and statistical significance was assessed by the log-rank test. 
 
2-2-7 Molecular modeling 
 
All computations were performed with Molecular Operating Environment (MOE) 
version 2003.01 (Chemical Computing Group, Montreal, QC, Canada). Sequence 
alignment and homology modeling of Src-family proteins were performed with 
MOE-Align and MOE-Homology, respectively. The X-ray coordinates of the imatinib/Abl 
cocrystal structure [43] were used as the template. NS-187 was manually docked into 
the binding site. Because of the structural similarity between NS-187 and imatinib, the 
mode of binding of NS-187 was assumed to be very similar to that of imatinib, and 
typical hydrogen-bonding interactions were retained: the nitrogen of the terminal 
pyrimidine ring with the backbone-NH of Met318, the nitrogen of the anilino group with 
the OH of Thr315, the amide-NH with the side-chain carboxylate of Glu286, and the 
amide-CO with the backbone-NH of Asp381. The energy of the models thus obtained 
was minimized by using the Merck Molecular Force Field (MMFF94s) method [44]. The 
amino acids within 0.7 nm (7 Å) of NS-187 were fully minimized, and changes in the 
structures of NS-187 and around the amino acids were small. Figures were prepared 
with PyMOL version 0.97 (DeLano Scientific, South San Francisco, CA). 
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2-3 Results 
 
2-3-1 NS-187 blocks the wild-type Bcr-Abl autophosphorylation and its 
downstream signaling 
 
NS-187, 
N-[3-(4,5’-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[3S]-3-(dimethylamino)pyrrolidin-1-
yl}methyl)-3-(trifluoromethyl)benzamide (Figure 2-1A), was discovered by screening for 
potent and selective Bcr-Abl kinase inhibitors. We compared the ability of NS-187 and 
imatinib to inhibit the tyrosine kinase activity of wild-type (wt) Bcr-Abl by first testing by 
Western blot analysis whether the protein is autophosphorylated in Bcr-Abl–positive 
K562 cells and Ba/F3 cells transfected with wt Bcr-Abl (Ba/F3-wt) when the cells are 
treated with either drug (Figure 2-1B-C). Its autophosphorylation status in 293T cells 
transfected with wt Bcr-Abl was also examined. The IC50 values of NS-187 against wt 
Bcr-Abl in K562 and 293T cells were 11 and 22 nM, respectively (Table 2-1). The 
corresponding values for imatinib were 280 and 1200 nM. Thus, NS-187 was 25 and 55 
times more potent than imatinib, respectively, in blocking Bcr-Abl autophosphorylation 
(Table 2-1). 
  The effect of NS-187 and imatinib on the tyrosine kinase activity of platelet-derived 
growth factor receptor (PDGFR), c-Kit, and epidermal growth factor receptor (EGFR) 
were also examined. NS-187 suppressed PDGFR and c-Kit phosphorylation with IC50 
values very similar to those of imatinib (Figure 2-1E-F). The ranking of IC50 with respect 
to imatinib is PDGFR > c-Kit > Bcr-Abl, whereas the ranking with respect to NS-187 is 
Bcr-Abl > PDGFR > c-Kit (Table 2-1). Neither NS-187 nor imatinib inhibited EGFR at 
clinically relevant concentrations (Figure 2-1G). 
The downstream mediators of Bcr-Abl, CrkL, and ERK are dephosphorylated on 
treatment with imatinib [45]. Examination of the intracellular phosphorylation status of 
CrkL and ERK revealed that NS-187 inhibited the phosphorylation of CrkL and ERK in 
K562 cells at much lower concentrations than did imatinib (Figure 2-2A-B). The 
inhibition of phosphorylation was also observed in Ba/F3-wt cells (Figure 2-2C-D). Thus, 
NS-187 was more potent Bcr-Abl inhibitor than was imatinib. 
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Table 2-1.  Ability of NS-187 and imatinib to inhibit the phosphorylation 
of Bcr-Abl and other tyrosine kinases at the cellular level. 
 
K562 cells were examined for Bcr-Abl phosphorylation after treatment with 
NS-187 or imatinib by Western blot analysis with Bcr-Abl–specific antibodies, 
as were 293T or Ba/F3 cells transfected with wt or point mutants of Bcr-Abl. 
NHDF, NCI-H526, and A431 cells were examined for PDGFR, c-Kit, or EGFR 
phosphorylation, respectively, after treatment with first NS-187 or imatinib and 
then PDGF, SCF, or EGF, respectively, by Western blot analysis with the 
corresponding antibodies. 
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B                                  C 
 
D                                  E 
 
F                                  G 
 
Figure 2-1.  Structure and activity of NS-187. 
Chemical structures of NS-187 (A). K562 cells (B), Ba/F3-wt cells (C), and 
Ba/F3-E255K cells (D) were incubated for 1.5 hours with the indicated 
concentrations of each compound. Serum-starved NHDF cells (E), NCI-H526 
cells (F), and A431 cells (G) were incubated for 1.5 hours with each compound 
prior to stimulation for 10 minutes with PDGF, SCF, or EGF, respectively. Cells 
were then lysed and subjected to Western blot analysis with 
antiphosphotyrosine antibody (B-G), anti–c-Abl antibody (B-D), anti-PDGFR 
antibody (E), anti–c-Kit antibody (F), or anti-EGFR antibody (G). p indicates 
phosphorylated. 
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Figure 2-2.  Effect of NS-187 on intracellular phosphorylation of CrkL 
and ERK. 
NS-187 inhibits the phosphorylation of CrkL and ERK in cells expressing wt 
Bcr-Abl or the E255K Bcr-Abl mutant but not in cells expressing the T315I 
Bcr-Abl mutant. K562 (A-B), Ba/F3-wt (C-D), Ba/F3-E255K (E-F), or 
Ba/F3-T315I (G-H) cells were incubated for 1.5 hours with the indicated 
concentrations of each compound. Cells were then lysed and subjected to 
Western blot analysis with antiphosphotyrosine antibody (A-H), anti-CrkL 
antibody (A,C,E,G), or anti-ERK1 antibody (B,D,F,H). The phosphorylated 
forms of CrkL (p) migrate more slowly than the unphosphorylated forms. 
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2-3-2 NS-187 inhibits the tyrosine phosphorylation of 12 of 13 known 
kinase domain point mutants 
 
More than 30 point mutations within the Abl kinase domain have been reported [46]. 
The ability of NS-187 to inhibit 13 of these mutant Bcr-Abl kinases was tested by 
constructing and purifying the mutant kinase domains and then subjecting them to in 
vitro kinase assays in the presence of NS-187 or imatinib. NS-187 at physiologically 
obtainable concentrations inhibited the phosphorylation of Bcr-Abl harboring the M244V, 
G250E, Q252H, Y253F, E255K, E255V, F317L, M351T, E355G, F359V, H396P, or 
F486S mutations but it did not inhibit the phosphorylation of the T315I mutant (Table 
2-2). For all mutants except T315I, the IC50 for imatinib was at least 5 times as high as 
the corresponding value for NS-187. 
  The effect of NS-187 on 2 of the mutants was also examined in whole cells by 
assessing the phosphorylation of Bcr-Abl with the E255K or the T315I mutation in Ba/F3 
cells (Ba/F3-E255K and Ba/F3-T315I). Unlike imatinib, NS-187 inhibited the 
phosphorylation of the E255K mutant at clinically relevant concentrations (Figure 2-1D). 
However, neither imatinib nor NS-187 had any effect on the phosphorylation of the 
T315I mutant (data not shown). 
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Table 2-2.  Effect of NS-187 and imatinib on the in vitro phosphorylation 
of purified wt and point mutated Abl kinase domains. 
 
The purified Abl kinase domains were subjected to in vitro kinase assays as 
described in “Materials and methods.” The enzyme concentration was 10 nM. 
 
2-3-3 NS-187 is a dual Bcr-Abl/Lyn tyrosine kinase inhibitor 
 
To test the ability of NS-187 to inhibit other tyrosine kinases, 79 tyrosine kinases were 
assayed with KinaseProfiler (Upstate). These included the 5 Src-family kinases Blk, Src, 
Fyn, Lyn, and Yes. The effects of 0.1 μM NS-187 and 10 μM imatinib were tested 
because these concentrations gave equal inhibition of Abl. At a concentration of 0.1 μM, 
NS-187 inhibited 4 of the 79 tyrosine kinases, that is, Abl, Abl-related gene (Arg), Fyn, 
and Lyn. Notably, at 0.1 μM, NS-187 did not inhibit PDGFRα, PDGFRβ, Blk, Src, or Yes 
(Figure 2-3). In contrast, 10 μM imatinib inhibited 9 tyrosine kinases, that is, Abl, Arg, Blk, 
FMS-like TK-3 (Flt3), Fyn, Lyn, PDGFRα, PDGFRβ, and p70S6K (data not shown), 
indicating that NS-187 inhibited Abl more specifically than did imatinib. To confirm the 
specificity of NS-187 against Lyn, the inhibitory effects of NS-187 against Abl, Src, and 
Lyn were tested. The IC50 values of NS-187 for these kinases were 5.8 nM, 1700 nM, 
and 19 nM, respectively, and those of imatinib were 106 nM, greater than 10000 nM, 
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and 352 nM, respectively. These findings suggest that NS-187 acts as an Abl-Lyn 
inhibitor while otherwise remaining highly specific for Bcr-Abl. 
 
 
Figure 2-3.  Kinase inhibition profile and the docking model. 
Kinase inhibition profile of NS-187 and Abl (panel B is the continuation of panel 
A). Seventy-nine tyrosine kinases, including 5 Src-family kinases (Blk, Src, Fyn, 
Lyn, and Yes; indicated by on the x-axis) were assayed by KinaseProfiler. At 
0.1 μM, NS-187 inhibited 4 of the 79 tyrosine kinases, namely, Abl, Arg, Fyn, 
and Lyn (indicated by red on the x-axis). 
 
2-3-4 NS-187 suppresses the growth of leukemic cell lines expressing 
wild-type Bcr-Abl or E255K mutant 
 
NS-187 suppressed the growth of the Bcr-Abl–positive cell lines K562 (Figure 2-4A), 
KU812 (Figure 2-4B), and Ba/F3-wt (Figure 2-4D) much more potently than did imatinib, 
but neither drug affected the proliferation of the Bcr-Abl–negative U937 cell line (Figure 
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2-4C). As to Bcr-Abl point mutants, NS-187 exhibited a concentration-dependent 
antiproliferative effect against Ba/F3-E255K (Figure 2-4E) but had no effect on 
Ba/F3-T315I cells within the concentration range tested (Figure 2-4F). Imatinib was less 
effective against all of the point mutants tested (Figure 2-4E-F). 
 
 
Figure 2-4.  Effect of NS-187 on in vitro growth of cell lines harboring 
Bcr-Abl. 
(A) Bcr-Abl–positive K562 cells, (B) Bcr-Abl–positive KU812 cells, (C) 
Bcr-Abl–negative U937 cells, (D) Ba/F3-wt cells, (E) Ba/F3-E255K cells, and 
(F) Ba/F3-T315I cells were treated with serial dilutions of NS-187 (●) or imatinib 
(○) for 3 days. Cell proliferation was assessed by means of the MTT assay. 
 
2-3-5 In vivo effects of NS-187 
 
In our preliminary experiments, when Balb/c mice were given NS-187 orally at a dose 
of 30 mg/kg, the pharmacokinetic parameters were as follows: Tmax, 2 hours; maximum 
concentration (Cmax), 661 ng/mL; area under the curve (AUC)0-∞, 2294 ng·h/mL; T1/2, 1.0 
hour; and bioavailability value (BA), 32%. The maximal tolerated dose (MTD) of NS-187 
in Balb/c or Balb/c-nu/nu mice was 200 mg/kg/d (100 mg/kg twice a day). Cmax for 
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NS-187 was estimated at 2226 ng/mL (4.0 μM) when mice were treated twice a day 
orally with 100 mg/kg of NS-187. 
  To test the effect of NS-187 on in vivo tumor growth, Balb/c-nu/nu mice were injected 
subcutaneously with Bcr-Abl–positive KU812 cells on day 0 and given NS-187 or 
imatinib orally twice a day from day 7 to day 17. At 20 mg/kg/d, imatinib inhibited tumor 
growth slightly, whereas at 200 mg/kg/d, it inhibited tumor growth almost completely. In 
contrast, at only 0.2 mg/kg/d NS-187 significantly inhibited tumor growth, whereas at 20 
mg/kg/d it completely inhibited tumor growth without any adverse effects (Figure 2-5A). 
When mice were treated with 0.2 or 20 mg/kg/d of NS-187, the estimated Cmax was 4 nM 
or 400 nM, respectively, suggesting that the in vivo effects of NS-187 were comparable 
to its in vitro effects (Figure 2-4B). The body weights of the treated tumor-bearing mice 
were not significantly different from those of untreated mice, even at a dosage of 200 
mg/kg/d NS-187 (data not shown). Thus, NS-187 was at least 10-fold more potent than 
imatinib in vivo with complete inhibition of tumor growth as the end point and at least 
100-fold more potent with partial inhibition as the end point. NS-187 was well tolerated 
by the mice. 
We also tested the ability of NS-187 to suppress tumor growth in another murine 
tumor model, namely, Balb/c-nu/nu mice that received Ba/F3-wt cells intravenously. The 
mice were treated orally with NS-187 or imatinib for 11 days starting on day 1. All 7 
untreated mice had died by day 23 due to leukemic cell expansion, whereas all mice 
treated with 400 mg/kg/d imatinib had died by day 25. Thus, imatinib had little effect on 
tumor growth in this model, whereas NS-187 significantly prolonged the survival of the 
mice in a dose-dependent manner compared with untreated mice (Figure 2-5B). We 
also examined the effect of longer exposure to NS-187 (25 days) in mice inoculated with 
5 × 104 instead of 1 × 106 Ba/F3-wt cells. NS-187 also prolonged the survival of these 
mice in a dose-dependent manner (data not shown). 
  We next examined the ability of NS-187 to block the in vivo growth of Ba/F3-E255K 
cells in Balb/c-nu/nu mice. Ba/F3-E255K-bearing mice were treated with NS-187 or 
imatinib for 26 days starting on day 1. The untreated mice and mice treated with 200 
mg/kg/d imatinib had all died by day 28 (Figure 2-5C). In contrast, NS-187 at 120 
mg/kg/d significantly prolonged survival compared with untreated mice (Figure 2-5C). 
NS-187 was also well tolerated by the mice. Thus, NS-187 was more potent than 
imatinib and could override the point mutation–based imatinib-resistance mechanism in 
vivo. 
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Figure 2-5.  Effect of NS-187 on in vivo tumor growth. 
(A) Balb/c-nu/nu mice received subcutaneous transplants of KU812 cells (day 
0) and were given vehicle (●), NS-187 (∆, 0.2 mg/kg/d; ▲, 20 mg/kg/d), or 
imatinib (□, 20 mg/kg/d; ■, 200 mg/kg/d) daily from day 7 to day 17. Data points 
represent the mean standard deviation calculated for 7 mice. Effect of NS-187 
in Ba/F3-leukemia model. (B) Survival of Balb/c-nu/nu mice that received 
transplants of Ba/F3-wt cells and given vehicle (black), NS-187 (pink, 6 
mg/kg/d; yellow, 20 mg/kg/d; green, 60 mg/kg/d; purple, 120 mg/kg/d; red, 200 
mg/kg/d), or imatinib (blue; 400 mg/kg/d) daily from day 1 to day 11. (C) 
Survival of Balb/c-nu/nu mice that received transplants of Ba/F3-E255K cells 
and given vehicle (black), NS-187 (red; 120 mg/kg/d), or imatinib (blue; 200 
mg/kg/d) daily from day 1 to day 26. *P < .05; **P < .01. 
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2-4 Discussion 
 
In view of the frequent development of imatinib resistance during the treatment of Ph+ 
leukemia, we sought to develop a novel agent to treat this disease that fulfills the 
following requirements for a ”post-imatinib” drug: (1) it inhibits Bcr-Abl, including variants 
with point mutations in the kinase domain, more effectively than does imatinib; (2) it has 
at most mild toxicity; and (3) it simultaneously inhibits another kinase whose activity is 
associated with imatinib resistance while remaining at least as specific for Bcr-Abl as is 
imatinib. With the aid of Bcr-Abl–docking modeling we have identified a candidate drug, 
NS-187, that inhibited the autophosphorylation of wt Bcr-Abl in K562 and 293T/wt cells 
more potently than did imatinib (Table 2-1). It also inhibited the phosphorylation of CrkL 
and ERK in K562 and BaF3/wt cells more strongly than did imatinib (Figure 2-2A-D; 
Table 2-1). Moreover, it suppressed the in vitro growth of Bcr-Abl–positive KU812 and 
K562 cells at much lower concentrations than did imatinib (Figure 2-4A-B). Significantly, 
NS-187 was at least 10-fold more potent than imatinib in mice bearing Bcr-Abl–positive 
tumors (Figure 2-5A-B) and had no adverse effects. Furthermore, not only was NS-187 
effective against wt Bcr-Abl but it also blocked the activity of Bcr-Abl with point 
mutations in the kinase domain (Figure 2-1D, 2-2E-F; Table 2-1, 2-2). In addition, it 
inhibited the in vitro growth of cells expressing mutant Bcr-Abl proteins (Figure 2-4E) 
and prolonged the survival of mice engrafted with Ba/F3-E255K cells (Figure 2-5C). The 
only point mutant that NS-187 failed to significantly inhibit was the T315I Bcr-Abl mutant. 
Imatinib failed to inhibit any of the point mutants tested. These findings show that 
NS-187 fulfills the first 2 requirements of a post-imatinib drug that were listed above. 
  Other post-imatinib agents such as PD166326 [29], SKI-606 [30], AP23464 [31], and 
BMS-354825 [32,33] were developed from Src inhibitors on the basis of the similarity 
between Abl and the Src-family proteins [47,48]. It has been shown that the 
simultaneous inhibition of any 2 of the Ras, signal transducers and activators of 
transcription 5 (STAT5), and phosphatidylinositol 3–kinase (PI3K) pathways leads to a 
synergistic enhancement of apoptosis in CML cells [49-51]. At present, research aimed 
at the development of effective therapies for Ph+ leukemias is focused not only on these 
signaling pathways but also on Lyn kinase, since acquired imatinib resistance may be 
mediated in part through the overexpression of Lyn [34,35]. Moreover, short interfering 
RNA (siRNA) targeting Lyn induces apoptosis in imatinib-resistant Ph+ leukemia cells 
[36]. Imatinib minimally inhibits Lyn (IC50, 352 nM). However, the dual Src-Abl inhibitor 
BMS-354825 significantly suppresses Lyn phosphorylation, and this is consistent with 
its greater antitumor activity in CML samples [33]. These observations suggest that the 
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ability of an agent to act simultaneously against Lyn and Abl will be advantageous in Ph+ 
leukemia therapy. However, it may be important for the activity of such a therapeutic 
agent to be limited to Abl and Lyn to avoid the possibility of adverse effects. It is well 
known that imatinib inhibits not only Abl but also PDGFR and c-Kit, and this may be 
responsible for adverse effects such as bone marrow suppression, periorbital edema, 
and hypopigmentation [52]. In addition, Src proteins are known to play important roles in 
osteoclastogenesis [37], the regulation of Ca2+ signaling [38], the modulation of vascular 
adaptations [39], and signaling through a variety of cell surface receptors [40]. For 
example, the vascular permeability activity of vascular endothelial growth factor (VEGF) 
specifically depends on the Src-family proteins Src or Yes [41]. These observations 
suggest that inhibition of PDGFR, c-Kit, or Src-family proteins could cause 
unpredictable adverse effects. We set out to discover a compound that would inhibit Lyn 
and Abl while inhibiting as few other kinases as possible. Although another novel 
Abl-specific inhibitor, AMN107, which like NS-187 is a 2-phenylaminopyrimidine–class 
compound, does not inhibit Lyn [53,54], we found that NS-187 inhibited Lyn in addition 
to Fyn but did not inhibit PDGFR, Src, Blk, or Yes at 0.1 μM, a concentration that 
adequately inhibits Abl kinase activity (Figure 2-3). 
  To investigate why NS-187 inhibited Lyn without simultaneously inhibiting Src, 
docking studies were performed using the cocrystal structure of imatinib bound to Abl 
[43]. Our proposed docking model of the NS-187/Abl complex is shown in Figure 2-6. 
The cocrystal structure reveals that the P-loop of Abl moves toward imatinib upon 
binding of imatinib to the protein [43]. This induced fit contributes to increased van der 
Waals interactions and stabilization of the inactive conformation of the complex. Such 
an induced fit is also likely to occur with NS-187 due to its structural similarity to imatinib. 
Moreover, as with imatinib, the NS-187/Abl complex is likely to be stabilized by the 
hydrogen-bonding interaction between the OH of Tyr253 and the side-chain NH2 of 
Asn322 as well as the water-mediated hydrogen-bonding interaction between the 
side-chain CO of Gln252 and the side-chain carboxylate of Asp325 (Figure 2-6). As to 
the variable binding of NS-187 to different Src-family proteins, it seems to be significant 
that while the amino acids at positions 253 and 325 are always Phe and Asp, 
respectively, the amino acid at position 252 is either Gln or Cys (Table 2-3). NS-187 
inhibited the Gln252-bearing proteins Abl, Fyn, and Lyn but had lower activity against 
the Cys252-bearing Src and Yes. This is probably because Gln, unlike Cys, readily 
forms hydrogen bonds [55]. As a result, the stabilization of the NS-187/Src complex by 
the induced movement of the P-loop is weaker when Cys252 is present than when 
Gln252 is present. Thus, induced fit of NS-187 to the kinase is likely to be important for 
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its ability to block the activity of the kinase. Our docking models support the notion that 
NS-187 is more specific for Lyn than for Src. 
 
 
Figure 2-6.  Close view of the docking model of NS-187 and Abl. 
Hydrogen-bonding interactions are shown as white broken lines. Movement of 
the P-loop shown in pink and the hydrogen-bonding interactions of the amino 
acids shown in sky blue contribute to stabilize the complex. 
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Table 2-3. Relationship between the amino acid at position 252 in 
Src-family proteins and the ability of NS-187 to inhibit its 
phosphorylation. 
 
 
  NS-187 is therefore an excellent candidate for an antileukemia agent. However, 
NS-187 is limited in one respect; that is, it cannot inhibit the phosphorylation of T315I 
Bcr-Abl. To our knowledge, an ATP-competitive inhibitor that can inhibit the 
phosphorylation of T315I Bcr-Abl has not yet been developed. This is probably because 
the T315I mutation eliminates a crucial hydrogen bond and sterically blocks the 
imatinib-binding site. According to our docking model, there is little space around T315, 
suggesting that it would be difficult for an ATP-competitive inhibitor of Bcr-Abl to inhibit 
the T315I mutant (data not shown). Only ON012380, a non–ATP-competitive inhibitor of 
Bcr-Abl, is effective against Bcr-Abl/T315I [56]. In addition, such non–ATP-competitive 
inhibitors may be less specific for Abl than are ATP-competitive inhibitors like NS-187. A 
compound that specifically inhibits Bcr-Abl/T315I is desirable even if it is difficult to 
develop. 
  In conclusion, NS-187 more potently inhibits Abl kinase activity than does imatinib, 
and its inhibitory activity is less affected by point mutations in the Abl kinase domain. 
Moreover, NS-187 also inhibits Lyn while otherwise maintaining a high specificity for 
Bcr-Abl. The efficacy and safety of NS-187 for Ph+ leukemias is expected to be verified 
by early-phase clinical trials. 
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Chapter 3 
 
Evaluation of NS-187 in mice models of 
imatinib-resistant chronic myeloid leukemia 
 
 
3-1 Introduction 
 
Efficacy of imatinib mesylate is limited in accelerated/ blastic-phase chronic myeloid 
leukemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukemia 
(Ph+ ALL) [20,21]. More than half of the cases of resistance to imatinib are attributable 
to the point mutations in the Abl kinase domain [19]. Recently, the overexpression of Lyn 
kinase has been suggested as another mechanism of imatinib-resistance [34]. 
  We have developed NS-187, which has a 25–55-fold greater potency than imatinib to 
inhibit Abl kinase and which simultaneously inhibits Lyn kinase. We have shown that 
NS-187 inhibits the kinase activity of 12 of 13 variant Abl kinases with clinically relevant 
mutations and suppresses the proliferation of cells expressing Bcr-Abl/E255K [57]. 
However, its in vitro and in vivo antiproliferative effects against other mutant Abl kinases 
have not yet been reported. Because in vitro results do not always correlate with in vivo 
efficacy, we herein examined the in vitro and in vivo effects of NS-187 on seven mutated 
Bcr-Abl proteins and shown that NS-187 had excellent in vivo anti-leukemic activity 
which correlated well with its in vitro effects. 
 
 
3-2 Materials and Methods 
 
3-2-1 Reagents and cell lines 
 
NS-187 and imatinib was synthesized by Nippon Shinyaku Co. Ltd. (Kyoto, Japan) 
[58]. Ba/F3 cell lines expressing p210 Bcr-Abl/wild-type, M244V, G250E, Q252H, Y253F, 
T315I, M351T or H396P were established as previously described [57]. 
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3-2-2 Cell viability, immunoblotting and kinase assay 
 
Cells under exponential growth were treated with serial dilutions of the compounds, 
and incubated for 3 days. Cell viability was determined by assay with MTT (Nacalai 
Tesque, Kyoto, Japan). Cells treated with serial dilutions of NS-187 for 3 h, were lysed 
and equal amounts of cell lysates were analysed by Western blotting as described 
elsewhere [57]. Tyr393-phosphorylated Abl was determined by immunoblotting with 
anti-phospho-c-Abl (Tyr412) (Cell Signaling Technology, Beverly, MA) (Tyr412 in c-Abl 
corresponds to Tyr393 in Bcr-Abl). Each mutant form of Abl at a concentration of 10nM 
was subjected to in vitro kinase assays with the SignaTECTTM PTK assay system 
(Promega, Madison, WI). 
 
3-2-3 Ba/F3 leukemia model 
 
All procedures involving animals were approved by the institutional review board at 
Nippon Shinyaku. BALB/cA Jcl-nu mice were injected intravenously with 1 x 106 cells 
and randomized into groups of five on day 1. The mice were administered orally with 
NS-187 (100 mg/kg/dose), imatinib (200 mg/kg/dose) or vehicle (0.5% methylcellulose) 
twice daily from day 2 through day 12. Survival analysis was performed by the 
Kaplan–Meier method and statistical significance was assessed by the log-rank test. 
The prolongation of survival was calculated as the mean survival of mice treated with 
NS-187 or imatinib as a percentage of the mean survival of vehicle-treated control mice, 
and denoted T/C (%). 
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3-3 Results and discussion 
 
3-3-1 In vitro effects of NS-187 in imatinib-resistant cell lines 
 
We herein examined the effects of NS-187 or imatinib on intracellular Bcr-Abl tyrosine 
phosphorylation which have not been previously reported. NS-187 inhibited both 
wild-type and mutated Bcr-Abl intracellular phosphorylation with a mean IC50 value of 
140 nM, except Bcr-Abl/T315I (Figure 3-1A). Bcr-Abl/wild-type, Q252H and M351T 
were especially sensitive to NS-187. Furthermore, NS-187 potently suppressed the 
growth of these cells, especially cells expressing Bcr-Abl/wild-type, Q253H, Y253F or 
M351T, though it did not suppress the growth of cells expressing Bcr-Abl/T315I (Figure 
3-1B). Imatinib, meanwhile, was much less active against all cell lines tested (Figure 
3-1C). These data indicate that NS-187 greatly inhibited not only the intracellular 
phosphorylation of most mutated Bcr-Abl kinases, but also the proliferation of cells 
expressing those kinases. 
  Since phosphorylation on Tyr393 is considered to stabilize the activation loop in the 
open conformation seen in the active kinase [43,59], the stronger efficacy of NS-187 
compared to imatinib could be explained by its effects on the Tyr393-phosphorylated 
form of Bcr-Abl. Imatinib inhibited the Tyr393-unphosphorylated form of Bcr-Abl with an 
IC50 value of 35 nM but had little effect on the phosphorylated form (Figure 3-1D–F). In 
contrast, NS-187 effectively inhibited the kinase activity of both Tyr393-phosphorylated 
and Tyr393-unphosphorylated forms of Bcr-Abl with respective IC50 values of 72 and 30 
nM, suggesting that NS-187 may have a sufficiently high affinity for Bcr-Abl to enable it 
to bind even to an unfavourable conformation. 
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Figure 3-1.  In vitro effects of NS-187. 
(A) Ba/F3 cells expressing the indicated mutant forms of Bcr-Abl were 
incubated with NS-187 or imatinib for 3 h. Cells were lysed and equal amounts 
of protein were analysed by immunoblotting with an anti-phosphotyrosine 
antibody. The amounts of phosphorylated protein were assessed by band 
densitometry. (B and C) Ba/F3 cells expressing the indicated mutant forms of 
Bcr-Abl were treated for 3 days with serial dilutions of NS-187 (B) or imatinib 
(C). Cell proliferation was determined by MTT analysis. (D) The Tyr393 
unphosphorylated (lane a) and phosphorylated (lane b) forms of Abl kinase 
domain. (E and F) Inhibitory effects of NS-187 or imatinib on the kinase activity 
of the Tyr393-unphosphorylated (E) and the Tyr393-phosphorylated (F) forms 
of Abl. The data shown are representative of three independent experiments. 
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3-3-2 In vivo activity of NS-187 in an imatinib-resistant mouse leukemia 
model 
 
To determine whether the in vitro inhibition of the growth of imatinib-resistant cells by 
NS-187 would be observed in an in vivo mouse leukemia model, mice were injected 
intravenously with Ba/F3 cells expressing either wild-type or mutant forms of Bcr-Abl. 
Mice which received Ba/F3 cells expressing Bcr-Abl/wild-type or any mutant form of 
Bcr-Abl except Bcr-Abl/T315I showed significant prolongation of survival by NS-187 at a 
dosage of 200 mg/kg/day without any apparent signs of toxicity (Figure 3-2A–H). This is 
consistent with the in vitro results. In contrast, imatinib even at a dosage of 400 
mg/kg/day was much less effective. 
  To assess the in vivo activity of NS-187 against mutated Bcr-Abl, the prolongation of 
survival, T/C (%), due to NS-187 or imatinib was calculated and is shown together with 
the IC50 values for NS-187 in the in vitro inhibition of cell growth (Figure 3-2I). NS-187 
resulted in the highest observed T/C (%) values in Ba/F3 leukemia cells expressing 
Bcr-Abl/wild-type, Q252H or M351T, in good agreement with the in vitro data. Moreover, 
the rank-order of the IC50 values for cell growth inhibition was clearly inversely 
correlated with T/C (%) in NS-187-treated mice (Figure 3-2I). Thus, the in vitro activity of 
NS-187 mirrored its efficacy in the in vivo mouse model of leukemia, a result which 
suggests that NS-187 will be clinically effective. 
  In conclusion, NS-187, which inhibited both Tyr393-phosphorylated and 
Tyr393-unphosphorylated forms of Bcr-Abl, suppressed the intracellular 
phosphorylation of mutated Bcr-Abl proteins and significantly prolonged the survival of 
mice which had received leukemic cells expressing mutated Bcr-Abl proteins. These 
data suggest that NS-187 is a promising agent for CML and Ph+ ALL which will extent to 
the treatment of imatinib-resistant patients with Bcr-Abl mutations. 
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Figure 3-2.  In vivo activity of NS-187 in an imatinib-resistant mouse 
leukemia model. 
(A–H) BALB/cA-nu mice were intravenously injected with Ba/F3 cells 
expressing the indicated mutant forms of Bcr-Abl on day 1. The mice were 
orally administered twice daily with NS-187 (green), imatinib (blue) or vehicle 
(red) from day 2 through day 12. The survival of the mice was assessed by the 
method of Kaplan and Meier. Each group contained five mice. (I) T/C (%) for 
NS-187 or imatinib. T/C (%) is shown as the average for three independent 
Ba/F3 clones expressing the same Bcr-Abl mutant. The Bcr-Abl mutants on the 
horizontal axis are aligned in ascending order of the IC50 values for NS-187 for 
the inhibition of cell growth. Data are presented as means ± S.D. of at least 
three independent experiments. 
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Chapter 4 
 
Discovery and characterization of NS-018, a 
selective JAK2 tyrosine kinase inhibitor, for the 
treatment of myeloproliferative neoplasms 
 
 
4-1 Introduction 
 
The breakpoint cluster region-abelson (BCR-ABL) negative myeloproliferative 
neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), 
and primary myelofibrosis (PMF) [60.61]. Current treatment options for MPNs, and 
especially for PMF, are limited and largely palliative with the notable exception of 
allogeneic stem cell transplantation [62]. A somatic point mutation at codon 617 of 
Janus kinase 2 (JAK2) tyrosine kinase (JAK2V617F) has been shown to occur in 
approximately 95% of patients with PV and approximately 50% of patients with ET and 
PMF [63-67]. JAK2V617F is a constitutively activated kinase that activates the 
JAK/STAT signaling pathway and dysregulates cell growth and function. Expression of 
JAK2V617F transforms hematopoietic cells to cytokine-independent growth in vitro and 
causes MPN-like diseases in mice after bone marrow transplantation [64,68-71]. 
Transgenic mice expressing JAK2V617F also develop MPN-like diseases [72-77]. In 
addition, other somatic mutations leading to aberrant JAK2 activation, that is, activating 
mutations in exon 12 of JAK2 and mutations at codon 515 of the thrombopoietin 
receptor (MPLW515L/K), have been identified in JAK2V617F-negative MPN patients 
[78,79]. These findings suggest that the inhibition of aberrant JAK2 activation would 
have a therapeutic benefit, and several JAK2 inhibitors are currently in clinical trials for 
patients with MPNs [80,81]. 
NS-018 is a newly discovered, orally bioavailable, small-molecule inhibitor of JAK2 
that is competitive with adenosine triphosphate (ATP). In the present study, we describe 
the preclinical characterization of NS-018 and report on its potent and selective 
inhibitory activity against JAK2 and Src-family kinases and promising in vitro and in vivo 
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activity against constitutively active JAK2 mutants. 
 
 
4-2 Materials and Methods 
 
4-2-1 In vitro kinase assay 
 
The kinase domains of human JAK1, JAK2, JAK3, and TYK2 were purchased from 
Carna Biosciences. Each kinase was incubated in a reaction medium containing serial 
dilutions of NS-018, biotinylated-peptide substrate, ATP, and MgCl2 in a 
streptavidin-coated plate for 1 h at 30°C. Phosphorylated substrates were 
spectrophotometrically detected with horseradish peroxidase-linked antibody (PY-20; 
BD Bioscience) and TMB (3,3',5,5'-tetramethylbenzidine) solution (Sigma Aldrich). The 
concentrations required to give 50% inhibition (IC50) were estimated by fitting the 
absorbance data to a logistic curve with SAS version 8.2 (SAS Institute). The inhibitory 
effect of NS-018 was tested against a panel of 53 kinases by Carna Biosciences 
according to their internal protocol. 
 
4-2-2 Cell lines 
 
The human JAK2V617F and MPLW515L genes were generated by site-directed 
mutagenesis and cloned into the pDON-AI-2-Neo retroviral vector (Takara Bio), and the 
TEL-JAK2 and TEL-JAK3 genes were cloned into the pMYs retroviral vector (Cell 
Biolabs). Ba/F3 cells (Riken BRC Cell Bank) were cultured in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (FBS) and 10% murine Interleukin-3 (IL-3) 
Culture supplement (BD Biosciences). Ba/F3-JAK2V617F, Ba/F3-MPLW515L, 
Ba/F3-TEL-JAK2, and Ba/F3-TEL-JAK3 cells were generated by retroviral infection with 
the pDON-AI-2-Neo/φMP34 or pMYs/Plat-E packaging system followed by selection for 
IL-3-independent growth. The clones used were confirmed to show exogenous gene 
expression by reverse transcriptase polymerase chain reaction and sequencing. SET-2 
and CMK cells were from the German Collection of Microorganisms and Cell Cultures 
(DSMZ), and K-562, U-937, and SKM-1 cells were from Health Science Research 
Resources Bank. All cell lines were cultured in RPMI-1640 containing 10% or 20% FBS. 
 
4-2-3 Cellular assay 
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Cell lines were used after reaching 70–90% confluence. For cell growth assay, cells 
were seeded in 96-well plates at densities optimized for growth rate (transformed Ba/F3 
cell lines at 1 × 103 cells/well, SET-2 cells at 1 × 104 cells/well, MV4-11 cells at 2 × 104 
cells/well, and other cell lines at 5 × 103 cells/well). The next day, cells were treated with 
serial dilutions of NS-018, and incubated for 72 h at 37°C with 5% CO2. Viability was 
measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
IC50 values were estimated with SAS version 8.2.  
For western blot analysis, Ba/F3-JAK2V617F cells were treated with increasing 
concentrations of NS-018 for 3 h and total cell lysates were prepared. Lysate samples 
were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), transferred to a polyvinylidene difluoride (PVDF) membrane, and probed 
with antibody specific for phospho-STAT5 (Tyr694), phospho-STAT3 (Tyr705), 
phosphor-p44/42 MAPK (ERK), STAT5, STAT3, or p44/42 MAPK (ERK) (Cell Signaling 
Technology). Antibodies were detected with the appropriate horseradish 
peroxidase-linked secondary antibodies (GE Healthcare) and membranes were 
developed with the ECL Plus western blotting detection system (GE Healthcare). 
Images were acquired with the ChemiDoc imaging system and analyzed with Quantity 
One software (Bio-Rad Laboratories).  
For apoptosis assay, Ba/F3-JAK2V617F cells were treated with increasing 
concentrations of NS-018 for 48 h, stained with annexin V and propidium iodide (BD 
Biosciences), and analyzed with a FACSCalibur flow cytometer (BD Biosciences). For 
the DNA fragmentation assay, Ba/F3-JAK2V617F cells were treated with NS-018 for 29 
h and DNA was extracted with the ApopLadder Ex Kit (Takara Bio). DNA fragmentation 
was assessed by agarose gel electrophoresis with ethidium bromide staining and 
analyzed with ChemiDoc Quantity One. 
 
4-2-4 Colony formation assay 
 
Peripheral blood mononuclear cells from PV patients with the JAK2V617F mutation or 
healthy volunteers were collected with informed consent and Institutional Review Board 
approval. A total of 2 × 105 cells were treated with increasing concentrations of NS-018 
in MethoCult H4534 methylcellulose medium (StemCell Technologies) supplemented 
with or without 3 U/mL erythropoietin. Experiments were performed in triplicate. Burst 
forming unit-erythroid (BFU-E) were counted on day 14. IC50 values were estimated with 
SAS version 8.2. 
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4-2-5 Mouse Ba/F3-JAK2V617F disease model 
 
The study was conducted in compliance with the Law for the Humane Treatment and 
Management of Animals (Law No. 105, 1973, as revised on 1 June 2006). Female 
BALB/c nude mice (Japan SLC) were placed in blanket cages in an environment 
maintained at 21–25°C and 45–65% relative humidity, with artificial illumination for 12 h 
and a ventilation frequency of at least 15 times per hour. They were allowed free access 
to food pellets and tap water. Ba/F3-JAK2V617F cells (106 per mouse) were inoculated 
intravenously into seven-week-old mice. Administration of vehicle (0.5% 
methylcellulose) or NS-018 twice daily by oral gavage began the day after cell 
inoculation. Survival was monitored daily, and moribund mice were humanely killed and 
their time of death was recorded for purposes of survival analysis. In a parallel study, all 
mice were humanely sacrificed after eight days of administration, and their spleens 
were removed and weighed. 
 
4-2-6 JAK2V617F transgenic mice 
 
The generation and genotyping of transgenic mice (BDF1 strain) were carried out as 
previously described [74]. At 12 weeks after birth, treatment with vehicle or NS-018 was 
begun by oral gavage and was continued twice a day on weekdays for 24 weeks. The 
body weight of the mice was measured weekly. Peripheral blood was drawn monthly 
into heparin-coated glass capillary tubes, and hematological parameters were 
determined with a Celltac α hematology analyzer (Nihon Kohden). For fractional 
analysis of white blood cells, nucleated cells were stained with fluorescently conjugated 
antibodies specific for Mac1, Gr1, B220, and CD3 (BD Biosciences) and the percentage 
of each fraction was determined with a FACSCalibur. The fractional cell number was 
computed by multiplying the percentage by the total white blood cell count. 
All mice were humanely sacrificed at the end of treatment, and terminal blood 
samples and organs were taken. For flow cytometric analysis of spleen and bone 
marrow, cells were treated with hemolysis buffer, washed in phosphate-buffered saline 
(PBS) containing 2% FBS, and treated with biotinylated antibodies specific for 
lineage-antigens (CD3, CD4, CD8, Gr1, Mac1, B220, CD19, and Ter119) for 30 min on 
ice. After washing, cells were treated with fluorescently conjugated antibodies (BD 
Biosciences) for 90 min. Antibodies for hematopoietic stem cell staining were 
APC-conjugated c-Kit, FITC-conjugated CD34, and PE-conjugated Sca-1. Antibodies 
for myeloid progenitor staining were biotin-conjugated IL7Rα, APC-conjugated c-Kit, 
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FITC-conjugated CD34, PE-conjugated Sca-1, and PE-Cy7-conjugated FcγR. 
Antibodies for megakaryocytic progenitor staining were APC-conjugated c-Kit, 
PE-conjugated CD9, PE-Cy7-conjugated FcγR, and FITC-conjugated CD41. Antibodies 
for erythrocyte progenitor staining were FITC-conjugated CD71 and PE-conjugated 
TER119. After washing, cells were resuspended in PBS containing 2% FBS and 
propidium iodide, and analyzed with a MACSQuant flow cytometer (Miltenyi Biotec) and 
FlowJo software (Tree Star). 
For histological evaluation, tissues samples from liver, spleen, lung and femur were 
fixed in formalin, embedded in paraffin and cut for hematoxylin-eosin staining or Gomori 
silver staining according to standard protocols (Biopathology Institute). Histological 
slides were viewed under a BX50 microscope and photographed with an Olympus 
FX380 digital camera. 
 
4-2-7 Structural analysis 
 
The kinase domain of human JAK2 was expressed in Sf9 cells infected with 
recombinant virus and purified as described elsewhere [82]. The NS-018/protein 
complex was concentrated and crystallized by the hanging-drop method at 4°C. 
Diffraction data from flash-frozen crystals were collected at the BL32B2 beamline of the 
SPring-8 synchrotron facility (Hyogo, Japan) and processed with the HKL-2000 
package [83]. The structure was solved by molecular replacement with the program 
Phaser [84]. All computations were performed with Molecular Operating Environment 
(MOE) version 2009.10 (Chemical Computing Group). Figure 4-1 was prepared with 
PyMOL version 1.3 (Schrödinger, LLC). 
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4-3 Results 
 
4-3-1 NS-018 is a potent and selective JAK2 kinase inhibitor in vitro 
 
NS-018, 
(N-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-
2,6-diamine maleate), was discovered by screening for potent and selective JAK2 
inhibitors. In in vitro kinase assays, NS-018 was highly active against JAK2 with an IC50 
of 0.72 nM, and it had 30–50-fold greater selectivity for JAK2 over other Jak-family 
kinases such as JAK1, JAK3, and TYK2 (Table 4-1). The ability of NS-018 to inhibit 
other kinases was tested with a panel of 53 kinases in the presence of ATP at 
concentrations close to their respective Km values. NS-018 showed potent inhibition of 
Src-family kinases, notably SRC and FYN, as well as weak inhibition of ABL and FLT3 
with 45- and 90-fold selectivity for JAK2, respectively (Table 4-2). NS-018 showed a 
high degree of selectivity for JAK2 over many other tyrosine kinases (Table 4-2) and 
serine/threonine kinases (Table 4-3). 
 
Table 4-1.  In vitro effects of NS-018 on Jak-family enzyme activity. 
 
 
IC50, nM Fold selectivity over JAK2 
JAK2 0.72 1 
JAK1 33 46 
JAK3 39 54 
TYK2 22 31 
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Table 4-2.  Tyrosine kinase selectivity profile of NS-018. 
 
Tyrosine kinase Family name 
Inhibition at 100 
nM, % 
Fold selectivity 
over JAK2 
JAK2 Jak 101.6 1 
FYN Src 100.0 4 
SRC Src 100.6 5 
YES Src 100.1 11 
LYNa Src 91.2 25 
FGR Src 92.6 26 
LCK Src 97.5 29 
HCK Src 87.0 49 
ABL Abl 90.7 45 
FLT3 PDGFR 82.5 90 
CSK Csk 8.6 ND 
EGFR EGFR -8.5 ND 
EPHB4 Eph 19.3 ND 
FGFR1 FGFR 4.8 ND 
IGF1R InsR 12.0 ND 
ITK Tec 8.5 ND 
KDR VEGFR -2.2 ND 
MET Met -8.7 ND 
PDGFRa PDGFR 6.3 ND 
RET Ret 51.2 ND 
TIE2 Tie -0.1 ND 
TYRO3 Axl -6.9 ND 
ZAP70 Syk 16.4 ND 
 
The ability of NS-018 to inhibit 23 tyrosine kinases was tested at one 
concentration (100 nM) in the presence of ATP at concentrations close to their 
respective Km values. IC50 values were separately determined against the 
kinase which were shown to be inhibited more than 80% at 100 nM NS-018. 
ND, not done. 
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Table 4-3.  Serine/threonine kinase selectivity profile of NS-018. 
 
Serine/threonine kinase Kinase group Inhibition at 100 nM, % 
AKT1 AGC -5.1 
AMPKa1/b1/g1 CAMK -1.1 
AurA Other 18.6 
CaMK4 CAMK -1.4 
CDK2 CMGC 12.6 
CHK1 CAMK -14.5 
CK1e CK1 -3.3 
DAPK1 CAMK -53.0 
DYRK1B CMGC -1.7 
Erk2 CMGC -1.9 
GSK3b CMGC -1.4 
IKKb CAMK -3.6 
IRAK4 TKL -4.0 
JNK2 CMGC 2.3 
MAP2K1 STE 12.6 
MAPKAPK2 CAMK 1.9 
MLK2 TKL -14.6 
MST2 STE 11.0 
NEK2 Other -5.9 
p38a CMGC -3.4 
p70S6K AGC -2.6 
PAK4 STE 16.8 
PDK1 AGC -2.0 
PIM1 CAMK -9.8 
PKACa AGC 2.5 
PKCa AGC 3.7 
PKD2 CAMK 0.1 
RAF1 TKL -4.1 
ROCK1 AGC 4.8 
SGK AGC -6.8 
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4-3-2 Structural analysis of JAK2 kinase in complex with NS-018 
 
Phosphorylation of the activation loop (A-loop) is one of the most common 
mechanisms for regulating protein kinase activity, and it leads to the relocation of an 
Asp-Phe-Gly (DFG) motif located adjacent to the N-terminus of the A-loop [85]. The 
X-ray co-crystal structure of JAK2 in complex with NS-018 revealed that (1) Tyr residues 
at positions 1007 and 1008 in the A-loop were phosphorylated, (2) the phosphorylated 
A-loop lay outside the active-site cleft, and (3) NS-018 bound to JAK2 in the “DFG-in” 
active conformation (Figure 4-1). 
 
 
Figure 4-1.  X-ray co-crystal structure of NS-018 bound to JAK2 kinase. 
The surface of NS-018 is shown in pink, the backbone of JAK2 in slate, and the 
activation loop (A-loop) in cyan. Gly993 is located immediately N-terminal to 
the DFG motif. For clarity, only key residues are shown. 
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4-3-3 NS-018 inhibits JAK2-mediated signaling and proliferation and 
induces apoptosis 
 
To evaluate the effects of NS-018 on JAK2-mediated signaling, we exposed Ba/F3 
cells expressing JAK2V617F (Ba/F3-JAK2V617F) to increasing concentrations of 
NS-018 for 3 h and measured the level of phosphorylation of JAK2-mediated signaling 
components by Western blotting (Figure 4-2a). NS-018 inhibited the phosphorylation of 
STAT5, STAT3, and ERK in a dose-dependent manner, with maximal effects at 
approximately 100, 30, and 300 nM, respectively. 
We next assessed the antiproliferative activity of NS-018 against hematopoietic cell 
lines (Table 4-4). NS-018 suppressed the growth of Ba/F3-JAK2V617F cells with an IC50 
of 60 nM and the JAK2V617F-positive cell line SET-2 with an IC50 of 120 nM. NS-018 
also inhibited the growth of Ba/F3-MPLW515L cells, which is dependent on 
JAK2-mediated signaling due to an activating mutation of the thrombopoietin receptor, 
at similar concentrations. Ba/F3-TEL-JAK2 cells were highly sensitive to NS-018, but 
Ba/F3-TEL-JAK3 cells were less sensitive. CMK cells, which are dependent on both 
JAK1 and JAK3 due to an activating mutation of JAK3 that signals through wild-type 
JAK1 [86], were also insensitive to NS-018. NS-018 showed weak antiproliferative 
activity against K-562 cells, which carry BCR-ABL, and MV4-11 cells, which carry an 
internal tandem duplication of FLT3. This selective antiproliferative activity was roughly 
consistent with the kinase inhibitory profile of NS-018. Additionally, NS-018 showed only 
minimal cytotoxicity against other hematopoietic cell lines such as SKM-1 and U-937. 
To determine whether the antiproliferative activity of NS-018 was accompanied by an 
increase in apoptosis, we exposed Ba/F3-JAK2V617F cells to various concentrations of 
NS-018 and determined the percentages of apoptotic cells by flow cytometry with 
annexin V/propidium iodide staining and assessed DNA fragmentation. NS-018 
treatment increased both the percentage of annexin V positive cells (Figure 4-2b) and 
the extent of DNA fragmentation (Figure 4-2c) in a dose-dependent manner. Thus, 
NS-018 both inhibited the phosphorylation of components of JAK2-mediated signaling 
and induced apoptosis in cell lines whose growth depended on JAK2 activation. 
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Figure 4-2.  Inhibition of JAK2-mediated signaling and induction of 
apoptosis in Ba/F3-JAK2V617F cells by NS-018. 
(a) Ba/F3-JAK2V617F cells were treated with increasing concentrations of 
NS-018 for 3 h and then lysed. Lysate was subjected to SDS-PAGE, 
transferred to a PVDF membrane and probed with the indicated antibodies. (b) 
Ba/F3-JAK2V617F cells were treated with 0–300 nM NS-018 for 48 h and 
tested for apoptosis by staining with annexin V/propidium iodide (PI). (c) 
Ba/F3-JAK2V617F cells were treated with NS-018 for 29 h prior to DNA 
extraction and DNA fragmentation was assessed by agarose gel 
electrophoresis. M indicates the DNA size marker. 
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Table 4-4.  Antiproliferative activity of NS-018 against hematopoietic cell lines. 
 
Cell line Origin Activated kinase IC50, nM 
Ba/F3-JAK2V617F Murine pro-B cell JAK2V617F 60 
Ba/F3-TEL-JAK2 Murine pro-B cell TEL-JAK2 11 
Ba/F3-TEL-JAK3 Murine pro-B cell TEL-JAK3 800 
Ba/F3-MPLW515L Murine pro-B cell MPLW515L 61 
SET-2 ET JAK2V617F 120 
CMK AML JAK3A572V 1100 
K-562 CML BCR-ABL 1600 
MV4-11 AML FLT3-ITD 730 
SKM-1 AML nk 4100 
U-937 Lymphoma nk 5800 
 
nk, not known; TEL, translocation ets leukemia; MPL, myeloproliferative 
leukemia virus oncogene; ET, essential thrombocythemia; AML, acute 
myelogenous leukemia; CML, chronic myelogenous leukemia; BCR-ABL, 
breakpoint cluster region-abelson leukemia virus; FLT3-ITD, fms-like tyrosine 
kinase 3-internal tandem duplication. 
 
4-3-4 NS-018 inhibits erythroid progenitor cell growth in primary PV 
patient samples 
 
To evaluate the efficacy of NS-018 against primary MPN patient cells, we performed 
colony formation assays with mononuclear cells from the peripheral blood of PV 
patients with the JAK2V617F mutation or of healthy volunteers. NS-018 inhibited the 
formation of BFU-E from healthy controls and PV patients in a dose-dependent manner, 
but the degree of inhibition was significantly greater for the PV patients (P = 0.011). 
Specifically, for three healthy controls, NS-018 inhibited erythroid colony growth with a 
mean IC50 of 952 ± 118 nM, while for four PV patients the corresponding IC50 was 529 ± 
36 nM (Figure 4-3a). We also assessed the efficacy of NS-018 in inhibiting the growth of 
erythropoietin-independent, endogenous erythroid colony (EEC) formation, a hallmark 
of JAK2V617F-positive MPN. NS-018 inhibited EEC formation with a mean IC50 of 224 ± 
26 nM (Figure 4-3b). Thus, NS-018 effectively inhibited erythroid progenitor cell growth 
in PV patient samples. 
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a       b 
 
Figure 4-3.  Effect of NS-018 on erythroid colony formation by PV patient 
cells. 
Mononuclear cells isolated from the peripheral blood of PV patients with the 
JAK2V617F mutation (n = 4) or healthy volunteers (n = 3) were treated with 
increasing concentrations of NS-018 in methylcellulose-based media with 
erythropoietin (a) or without erythropoietin (b). Burst forming unit-erythroid 
(BFU-E) were counted on day 14. Values represent the mean ± SEM. 
Statistical significance was assessed by the t-test (* P<0.05). 
 
4-3-5 NS-018 is effective in a mouse Ba/F3-JAK2V617F disease model 
 
We next evaluated the in vivo efficacy of NS-018 in a mouse acute disease model. 
Mice inoculated with Ba/F3-JAK2V617F cells showed marked splenomegaly and died 
within 2–3 weeks due to penetrant hematopoietic disease progression. NS-018, 
administered by oral gavage twice a day, significantly prolonged survival of the mice at 
dosages of 12.5 mg/kg or higher (Figure 4-4a). Although vehicle-treated mice had all 
died by day 19, all mice treated with 100 mg/kg NS-018 were still alive even on day 25. 
NS-018 also significantly reduced splenomegaly at dosages of 1.5 mg/kg or higher 
(Figure 4-4b). The weight and appearance of the spleens of mice treated with 50 mg/kg 
NS-018 were similar to those of uninoculated control mice. Thus, NS-018 was highly 
efficacious in this mouse model of acute disease. 
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a           b 
 
 
Figure 4-4.  Effect of NS-018 on survival and splenomegaly in a mouse 
Ba/F3-JAK2V617F disease model. 
Disease was established in BALB/c nude mice by intravenous injection of 1 × 
106 Ba/F3-JAK2V617F cells. (a) Survival curves. NS-018 was administered by 
oral gavage twice a day for 11 days at the indicated doses. Statistical 
significance was assessed by the log-rank test (* P<0.01 vs vehicle, eight mice 
per group). (b) Mice inoculated with Ba/F3-JAK2V617F were orally 
administered with the indicated doses of NS-018 twice a day. Uninoculated 
control mice (sham) received vehicle only. The day after the completion of eight 
days of administration, spleens were removed and weighed. Values represent 
the mean ± SEM. Statistical significance was assessed by the t-test (# P<0.01 
vs sham) and Dunnett’s test (* P<0.01 vs vehicle, five mice per group). 
 
4-3-6 Efficacy of NS-018 in mouse MPN model (JAK2V617F transgenic 
mice) 
 
Mice expressing JAK2V617F under the control of the H2Kb promoter (V617F-TG 
mice) show an MPN phenotype, including leukocytosis, thrombocytosis, progressive 
anemia, hepatosplenomegaly with extramedullary hematopoiesis, megakaryocyte 
hyperplasia and fibrosis in the bone marrow [74]. They also exhibit body weight loss and 
high mortality compared to wild-type controls. Their bone marrow cells show constitutive 
activation of STAT5 and cytokine-independent erythroid colony formation. In the present 
study, we tested the efficacy of NS-018 in this chronic MPN model. Before starting 
long-term administration, we confirmed that NS-018 inhibited constitutive 
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JAK2-mediated signaling in vivo. As expected, NS-018 inhibited the phosphorylation of 
STAT5 in Mac1+/Gr1+ myeloid cells from bone marrow of V617F-TG mice following a 
single oral administration at a dosage of 50 mg/kg (Figure 4-5). 
 
 
Figure 4-5.  Inhibition of STAT5 phosphorylation in JAK2V617F 
transgenic mice by NS-018. 
Wild-type (WT) or JAK2V617F transgenic (TG) mice were orally administered 
with NS-018 (50 mg/kg) or vehicle once. One hour after administration, bone 
marrow cells were collected and fixed immediately, and stained with 
fluorescently conjugated antibodies specific for Mac1, Gr1, and 
phospho-STAT5. The levels of phosphorylation of STAT5 in Mac1/Gr1- positive 
cells were determined by flow cytometry. 
 
After disease was established at 12 weeks after birth, V617F-TG mice were randomly 
assigned to treatment with NS-018 or vehicle. NS-018 was administered by oral gavage 
twice a day for 24 weeks at doses of 25 or 50 mg/kg, and the control groups received 
vehicle only. No signs of gross toxicity were observed during the 24 weeks of treatment. 
During the study, the peripheral blood count of the mice was monitored monthly (Figure 
4-6A-D). V617F-TG mice showed marked leukocytosis. After four weeks of NS-018 
treatment, the white blood cell count was reduced to 59% in the 25 mg/kg group and 
39% in the 50 mg/kg group compared to the vehicle-treated group, and the effect was 
maintained until the end of the study (Figure 4-6A). To determine which kinds of white 
blood cell increased, we performed a fractional analysis by flow cytometry. At eight 
Mac1/Gr1+ cells
pSTAT5
WT-vehicle
TG-vehicle
TG-50mg/kg
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weeks, the numbers of Mac1+/Gr1+ myeloid cells, B220+ B cells, and CD3+ T cells in 
V617F-TG mice were respectively 370-, 5.4-, and 8.8-fold greater than in wild-type mice 
(Figure 4-6B). In the 50 mg/kg group, the respective numbers fell to 98-, 3.3-, and 
5.3-fold. Although NS-018 reduced the numbers of all white blood cell types, the 
reduction in Mac1+/Gr1+ myeloid cells was the greatest. V617F-TG mice also showed 
progressive anemia (Figure 4-6C). The 25 mg/kg group followed the same course of 
reduction in red blood cell count as the vehicle-treated group. However, the 50 mg/kg 
group showed no reduction in red blood cell count even after 20 weeks, although the 
count was lower than that of wild-type mice. This indicated that treatment with 50 mg/kg 
NS-018 prevented the progression of anemia. V617F-TG mice showed thrombocytosis 
in the early stages, but the platelet count declined with time (Figure 4-6D). Platelet 
aggregation and giant platelets were observed in the peripheral blood of these mice.15 
NS-018 treatment resulted in sustained thrombocytosis. 
NS-018 treatment also reduced hepatosplenomegaly in a dose-dependent manner 
(Figure 4-6E). In the spleen, NS-018 treatment significantly decreased Mac1+/Gr1+ 
myeloid cells associated with extramedullary hematopoiesis and significantly increased 
B220+ B cells (Figure 4-6F). Consistent with the reduction in organ weights and 
infiltrating myeloid cells, the histopathological results showed that NS-018 markedly 
reduced cell invasion and restored normal architecture (Figure 4-6G). In the spleen of 
V617F-TG mice, the white pulp was blended throughout and partially preserved, and 
the red pulp was expanded by mainly myeloid cell invasion. However, NS-018 treatment 
resulted in a marked reduction in cell invasion and a restored architecture of the spleen 
(Figure 4-6Ga-d). In the liver and lung, extramedullary hematopoiesis consisting of 
myeloid cells and megakaryocytes was reduced in a dose-dependent manner (Figure 
4-6Ge-l) and almost completely disappeared in the 50 mg/kg group (Figure 4-6Gh, l). In 
contrast to the pathological improvement in these organs, NS-018 treatment had little 
impact on the progression of fibrosis and megakaryocyte hyperplasia in the bone 
marrow. 
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Figure 4-6.  Effect of NS-018 in JAK2V617F transgenic mice. 
JAK2V617F transgenic mice (TG) were divided into three groups and orally 
administered with vehicle, 25 mg/kg NS-018, or 50 mg/kg NS-018 (n = 34, 37, 
and 36, respectively) twice a day for 24 weeks. Wild-type mice (WT) received 
vehicle only (n = 27). (A) White blood cell (WBC), (C) red blood cell (RBC), and 
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(D) platelet (PLT) counts were monitored monthly. Values represent the mean ± 
SEM. Statistical significance was assessed by the t-test (* P<0.05, ** P<0.01 vs 
TG-vehicle). (B) Differences in cellular composition. Nucleated cells from 
peripheral blood were stained with fluorescently conjugated antibodies specific 
for Mac1/Gr1 (myeloid cells), B220 (B cells), and CD3 (T cells) and analyzed by 
flow cytometry. (E) The weight of liver and spleen were measured at the end of 
the treatment period. Values represent the mean ± SEM. Statistical significance 
was assessed by the t-test (# P < 0.01 vs WT-vehicle) or Dunnett’s test (* 
P<0.05, ** P<0.01 vs TG-vehicle). (F) Spleen cells were stained with 
fluorescently conjugated antibodies specific for Mac1/Gr1 (myeloid cells), B220 
(B cells), and CD3 (T cells) and analyzed by flow cytometry. (G) After NS-018 
treatment, tissue sections were prepared from spleen (a-d; original 
magnification ×40), liver (e-h; magnification ×200), and lung (i-l; magnification 
×200) for staining with hematoxylin and eosin. (H) The body weight of the mice 
was monitored weekly. (I) Total cholesterol in the serum at the end of the study. 
Values represent the mean ± SEM. Statistical significance was assessed by the 
t-test (# P<0.01 vs WT-vehicle) or Dunnett’s test (* P<0.01 vs TG-vehicle). (J) 
Survival curves of mice. Statistical significance was assessed by the log-rank 
test (# P<0.01 vs WT-vehicle, * P<0.01 vs TG-vehicle). 
 
4-3-7 NS-018 improves survival and compromised nutritional status in a 
mouse MPN model 
 
V617F-TG mice exhibited reduced body weight gain and high mortality compared to 
wild-type controls (Figure 4-6H, J). However, mice treated with 50 mg/kg NS-018 
progressively gained more weight than vehicle-treated mice, and their body weight was 
comparable to that of wild-type mice (Figure 4-6H). Total cholesterol was significantly 
decreased in the serum of V617F-TG mice compared with wild-type mice, indicating 
compromised nutritional status. However, in accordance with the body weight gain, total 
cholesterol was increased in the NS-018-treated groups at the end of the study (Figure 
4-6I). NS-018 also improved the survival of V617F-TG mice. During the 24-week study, 
12 of 34 mice died in the vehicle group, whereas 1 of 36 mice died in the 50 mg/kg 
group (Figure 4-6J). This corresponds to a statistically significant prolongation of 
survival in the 50 mg/kg group (P<0.01). Taken together, these results suggest that 
NS-018 reduced leukocytosis, anemia progression, hepatosplenomegaly, and 
extramedullary hematopoiesis, improved nutritional status, and prolonged survival in 
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V617F-TG mice. 
 
 
4-4 Discussion 
 
In view of the lack of satisfying treatment options for patients with BCR-ABL-negative 
MPNs, we sought to develop an orally bioavailable small-molecule therapeutic agent to 
treat these diseases. The discovery of the JAK2V617F and MPLW515L mutations in 
MPN patients suggests that the inhibition of aberrant JAK2 activation would have a 
therapeutic benefit for MPN patients. Our novel JAK2 inhibitor, NS-018, was found to be 
highly active against JAK2 with an IC50 of less than 1 nM and to have high selectivity for 
JAK2 over many other kinases. 
In addition to JAK2, NS-018 inhibited Src-family and ABL kinases with up to almost 
50-fold selectivity for JAK2 (Table 4-2). To investigate the structural factors determining 
the selectivity of NS-018, we carefully explored the binding site of the X-ray co-crystal 
structure of the complex of the human JAK2 kinase domain and NS-018 (Figure 4-1). 
Gly at position 993, which is located immediately N-terminal to the activation loop DFG 
motif, tightly fixed the position of NS-018. Because Gly is the smallest amino acid, we 
hypothesized that NS-018 effectively inhibites kinases with small amino acids at this 
position. In keeping with this hypothesis, NS-018 was active against Abl and Src-family 
kinases, which have Ala, the second smallest natural amino acid, at this position.28 
However, kinases belonging to the Axl, FGFR, InsR, Met, and Tie families have Gly or 
Ala at this position, yet NS-018 did not inhibit them. These kinases may have amino 
acids at other positions that prevent NS-018 binding. The remaining kinases listed in 
Table 4-2 have larger amino acids such as Cys, Ser, or Thr at this position, and NS-018 
did not inhibit these kinases. Furthermore, the Ser/Thr kinases listed in Table 4-3 also 
have larger amino acids such as Cys, Ser, Thr, Val, Leu, or Ile at the corresponding 
position, and NS-018 also did not inhibit these kinases. These results provide evidence 
that the selectivity of NS-018 is largely determined by the size of the amino acid at 
position 993. 
JAK and Src-family kinases work in concert to activate many signaling molecules [88]. 
Cooperation between SRC and JAKs is required for full activation of STAT3 [89]. Potent 
inhibition of STAT3 phosphorylation in Ba/F3-JAK2V617F cells by NS-018 (Figure 4-2a) 
may be explained by the simultaneous inhibition of JAK2 and Src-family kinases. 
Several reports have indicated the involvement of Src-family kinases in the 
pathogenesis of MPNs. For example, a TEL-lyn fusion gene has been identified in a 
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patient with primary myelofibrosis [90]. The Src-family kinase inhibitors dasatinib and 
PP2 have been shown to suppress erythropoietin-independent erythroid colony growth 
from PV [91,92]. Furthermore, SRC kinase preactivation is associated with platelet 
hypersensitivity in ET and PV patient samples [93]. On the other hand, LYN, FGR, and 
HCK have been reported to be independent of JAK2V617F-induced polycythemia in a 
murine retroviral bone marrow transplantation model [71]. Although the involvement of 
Src-family kinases in MPNs has not yet been fully clarified, simultaneous inhibition of 
JAK2 and some Src-family kinases is expected to be advantageous in preventing 
aberrant JAK2-STAT signaling and thereby curing the disease. 
NS-018 inhibited the growth of cells which depended on JAK2 activation with IC50 
values of 11–120 nM. Consistent with the selective inhibition by NS-018 of the 
enzymatic activity of JAK2 over that of JAK1 and JAK3, Ba/F3-TEL-JAK3 and CMK 
cells were less sensitive to NS-018. Weak inhibition of ABL and FLT3 kinases by 
NS-018 is the most likely explanation for its weak antiproliferative activity against K-562 
cells (which express BCR-ABL) and MV4-11 cells (which express an internal tandem 
duplication of FLT3). The difference between the selectivity of NS-018 in the 
enzyme-inhibition assay and in the cell growth assay may arise from a difference in the 
extent to which cell growth depends on kinase activation in these cell lines. The fact that 
NS-018 did not inhibit other Tyr or Ser/Thr kinases might explain its low general 
cytotoxicity against nontarget cells. 
The efficacy of several JAK2 inhibitors has been evaluated in an acute mouse 
Ba/F3-JAK2V617F disease model [94-96]. In the present study, NS-018 seemed as 
effective as these inhibitors in this model (Figure 4-4). These results demonstrate the in 
vivo potency of NS-018. To further evaluate the efficacy of NS-018 in a chronic MPN 
model, we performed long-term administration of NS-018 to transgenic mice expressing 
JAK2V617F. In contrast to other reports that several JAK2V617F transgenic mice tend 
to show polycythemia [72,73,75-77], our transgenic mice showed progressive anemia 
[74]. Although the reason for this is unclear, any impairments in the differentiation of 
erythrocyte progenitors to mature erythrocytes and the progression of bone marrow 
fibrosis are supposed to be related to anemia (unpublished data). Treatment with 50 
mg/kg NS-018 prevented the progression of anemia in these mice (Figure 4-6C). To 
assess the causes of differences in the peripheral blood count, we examined the effects 
of NS-018 on hematopoietic cellular compartments and differentiation in bone marrow 
and spleen by flow cytometric analysis. No significant differences were observed in the 
proportion of hematopoietic stem cells (CD34+/Kit+/Sca1+/Lineage-), common myeloid 
progenitors (CD34+/Kit+/Sca1-/FcγRlow/Lineage-), granulocyte/macrophage 
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progenitors (CD34+/Kit+/Sca1-/FcγRhigh/Lineage-), megakaryocytic/erythroid 
progenitors (CD34low/Kit+/Sca1-/FcγRlow/Lineage-), erythrocyte progenitors 
(CD71+/Ter119+), or megakaryocytic progenitors 
(CD41+/Kit+/CD9+/FcγRlow/Lineage-) in the NS-018-treated group compared with the 
vehicle-treated group (data not shown). Because the proportions of stem cells and 
progenitors in the spleen and bone marrow were not changed by NS-018 administration, 
it was assumed that erythrocyte progenitors did not increase. Additionally, serum levels 
of erythropoietin and thrombopoietin were not significantly different in NS-018-treated 
and vehicle-treated V617F-TG mice. Thus, the reason for the NS-018-dependent 
reduction in anemia progression remains unclear. 
V617F-TG mice also showed thrombocytosis in the early stages, but the platelet 
count slowly decreased with time. Because the megakaryocyte number in bone marrow 
in these mice was remained higher than in wild-type mice, platelet production was 
assumed not to have decreased. One possible explanation for the reduction in platelet 
count is enhancement of platelet trapping due to progressive splenomegaly. The 
sustained thrombocytosis caused by NS-018 treatment (Figure 4-6D) was considered to 
be the result of reduced splenomegaly. Another possible explanation for the 
platelet-count reduction in V617F-TG mice is a reduced platelet life span due to the 
enhanced platelet aggregation. It has been hypothesized that, in patients with MPNs, 
continuous leukocyte degranulation due to leukocyte activation might result in the 
consumption of factor V and protein S, leading to activated protein C resistance and 
increased risk of thrombosis [97]. Platelet aggregation has also been observed in 
V617F-TG mice [74]. Although NS-018 has been shown not to affect the clotting 
function of blood from normal rats (unpublished data), treatment with NS-018 might 
reduce platelet aggregation by suppressing leukocyte activation, thereby prolong 
platelet life span in these mice. 
Loss of appetite and deterioration in nutritional status are observed in patients with 
MPNs, especially myelofibrosis [98]. V617F-TG mice also exhibited reduced body 
weight gain and reduced total serum cholesterol levels, and NS-018 markedly increased 
both their body weight gain and their cholesterol levels (Figure 4-6H, I). These effects 
may have been brought about by an improvement in appetite through a reduction in the 
mechanical compression of the gastrointestinal tract resulting from hepatosplenomegaly, 
as well as inhibition of leptin signaling through JAK2. Improvement in nutritional status 
by NS-018 seemed to contribute to the prolonged survival of these mice. 
In summary, NS-018 significantly reduced leukocytosis, hepatosplenomegaly, and 
extramedullary hematopoiesis, and improved nutritional status in V617F-TG mice. All 
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these effects of NS-018 may contribute to the survival benefits observed in V617F-TG 
mice. Additionally, NS-018 inhibited erythroid colony formation by peripheral blood 
mononuclear cells from PV patients at concentrations significantly lower than those 
required for healthy controls (Figure 4-3). Examination of the X-ray co-crystal structure 
showing NS-018 bound to JAK2 in the “DFG-in” active conformation strongly suggests 
that NS-018 may inhibit constitutively activated JAK2 with the V617F mutation as well 
as or better than it inhibits activated wild-type JAK2. Overall, our results suggest that 
NS-018 will be effective in treating patients with MPNs. The efficacy and safety of 
NS-018 for MPNs is expected to be verified by early-phase clinical trials to begin in early 
2011. 
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Chapter 5 
 
Analysis of NS-018 for JAK2V617F mutant kinase 
selectivity 
 
 
5-1 Introduction 
 
Janus kinase 2 (JAK2) is a tyrosine kinase which plays an essential role in the 
cytokine signaling pathways that regulate hematopoiesis. Germline deletion of JAK2 in 
mice results in embryonic lethality due to a lack of hematopoiesis [99,100], and 
conditional JAK2 deletion in young adult mice severely impairs erythropoiesis and 
thrombopoiesis [101]. 
A somatic point mutation at codon 617 of JAK2, V617F, occurs in the 
BCR-ABL-negative myeloproliferative neoplasms (MPN), including polycythemia vera, 
essential thrombocythemia, and primary myelofibrosis [63-67]. The resulting mutant 
protein, JAK2V617F, is a constitutively activated kinase that activates multiple 
downstream signaling pathways, such as the signal transducer and activator of 
transcription (STAT), extracellular signal-regulated kinases (ERK) and Akt signaling 
pathways, and it transforms hematopoietic cells to cytokine-independent growth. The 
expression of JAK2V617F causes MPN-like diseases in mice after bone marrow 
transplantation (BMT) [68-71]. Transgenic mice expressing JAK2V617F also develop 
MPN-like diseases [72-77]. These findings suggest that the inhibition of aberrant JAK2 
activity would have therapeutic benefit, and accordingly several JAK2 inhibitors have 
been developed for the treatment of MPN [80,81,102-106]. 
JAK2 inhibitors show significant therapeutic benefit by reducing spleen size, relieving 
debilitating symptoms, and improving overall survival in clinical trials of these 
compounds in the treatment of myelofibrosis [105-107]. Although current JAK2 
inhibitors are therapeutically effective, they are reported to have hematologic adverse 
events, including anemia and thrombocytopenia [105-107]. 
NS-018, 
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(N-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-
2,6-diamine maleate) is a potent and selective inhibitor of JAK2 and Src-family kinases 
which is currently in early-phase clinical trials for MPN. In a previous study, NS-018 
prevented the progression of anemia in JAK2V617F transgenic mice as well as 
improving splenomegaly and survival [108]. However, the effect has not yet been 
confirmed in other animal models. Furthermore it remains unclear which characteristic 
feature of NS-018 contributes to this effect. In this study, we confirmed the effect of 
NS-018 on red blood cells in another myelofibrosis model mouse. We also report that 
NS-018 suppressed the growth of cells harboring JAK2V617F more strongly than that of 
cells harboring wild-type JAK2. 
 
 
5-2 Materials and Methods 
 
5-2-1 Production of retroviruses 
 
Murine JAK2WT (wild-type) and murine JAK2V617F cDNA [74] were cloned into the 
retroviral vector pMCs-IRES-GFP (Cell Biolabs, San Diego, CA, USA). Transient 
transfection of Platinum-E retroviral packaging cells (Cell Biolabs) was performed by 
using the FuGENE6 transfection agent (Promega, Madison, WI, USA) according to the 
manufacturer’s protocol. Retroviral supernatants were harvested after 48 h and used to 
transduce the murine interleukin-3 (IL-3) dependent pro-B cell line Ba/F3 or 
bone-marrow cells. 
 
5-2-2 JAK2V617F BMT mice 
 
Murine BMT experiments were performed as previously described [68,69]. Briefly, 
female BALB/c donor mice (Japan SLC, Hamamatsu, Shizuoka, Japan) were treated 
with 5-fluorouracil (150 mg/kg, intraperitoneal injection) to increase the number of 
cycling stem cells for retroviral transduction. Three days after injection, bone-marrow 
cells were harvested by flushing the femurs and tibias of the donor mice with 
phosphate-buffered saline. Mononuclear cells were isolated by Ficoll-Paque density 
gradient centrifugation and cultured for 24 h in αMEM medium supplemented with 20% 
fetal bovine serum and recombinant murine interleukin-6, stem cell factor, FMS-like 
tyrosine kinase 3 (flt3) ligand, and thrombopoietin (PeproTech; 50 ng/ml each). The cells 
were treated with retroviral supernatants in RetroNectin-coated dishes (Takara Bio, 
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Otsu, Shiga, Japan) for 72 h. The cells were then injected into the lateral tail vein of 
BALB/c recipient mice that had been irradiated with 2.5 Gy of gamma rays (2 × 105 cells 
per mouse). 
Ten days after transplantation, NS-018 was orally administered twice daily for 40 days 
at 50 mg/kg. After treatment, all mice were humanely killed and terminal blood samples 
and organs were collected. Hematological parameters were determined with an ADVIA 
120 hematology system (Siemens Healthcare, Erlangen, Germany). For survival 
analysis, the statistical significance of differences between vehicle and NS-018 groups 
was assessed by the log-rank test with SAS version 9.1.3. For blood count and spleen 
weight analyses, the statistical significance of differences between control and vehicle 
groups was assessed by the Welch test. If the control and vehicle groups were 
significantly different, the statistical significance of differences between the vehicle and 
NS-018 groups was assessed by the Welch test. For histological evaluation, tissues 
samples from spleens and femurs were fixed in formalin, embedded in paraffin and cut 
for hematoxylin–eosin staining or Watanabe silver staining according to standard 
protocols (KAC, Kyoto, Japan). Histological slides were viewed under an Olympus 
BX50 microscope and photographed with an Olympus FX380 digital camera. Studies 
were conducted in compliance with the Law for the Humane Treatment and 
Management of Animals (Law No. 105, 1 October 1973, as revised on 1 June 2006). 
 
5-2-3 Cell culture and growth assay 
 
Ba/F3 cells (Riken BRC Cell Bank, Tsukuba, Ibaraki, Japan) were cultured in 
RPMI-1640 medium supplemented with 10% fetal bovine serum and 20 ng/ml 
recombinant murine IL-3 (PeproTech, Rocky Hill, NJ, USA). Ba/F3-JAK2WT and 
Ba/F3-JAK2V617F cells were generated by retroviral infection with polybrene. 
For growth assays, cells were seeded in 96-well plates at 1 × 103 cells/well, treated 
with serial dilutions of compound, and incubated for 90 h at 37°C in 5% CO2. Viability 
was measured by WST-8 assay (Cell Counting Kit-8; Dojindo Laboratories, Kumamoto, 
Japan). The concentration required to give 50% inhibition (IC50) was estimated with SAS 
version 9.1.3 (SAS Institute, Cary, NC, USA). 
For colony formation assay, bone-marrow cells were harvested by flushing the femurs 
and tibias of JAK2V617F transgenic mice or WT control mice with phosphate-buffered 
saline. A total of 2 × 105 cells were treated with increasing concentrations of NS-018 in 
MethoCult M3334 methylcellulose medium (StemCell Technologies, Vancouver, BC, 
Canada) in the presence of 3 U/ml erythropoietin. Experiments were performed in 
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triplicate. Erythroid colony-forming units (CFU-E) were counted on day 3 and a two-way 
factorial analysis of variance was performed with SAS version 9.1.3. 
 
5-2-4 Structural analysis 
 
The acquisition of the X-ray co-crystal structure of NS-018 bound to JAK2 was 
described previously [108]. All published X-ray crystal structures were taken from the 
Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). Figure 3-5 and 3-6 were 
prepared with PyMOL version 1.3 (Schrödinger, New York, NY, USA). 
 
 
5-3 Results 
 
5-3-1 Efficacy of NS-018 in JAK2V617F BMT mice 
 
To assess the effect of NS-018 in a mouse model with a myelofibrosis-like disease, 
we established a JAK2V617F BMT mouse model. BALB/c mice were subjected to BMT 
with bone marrow donor cells retrovirally transduced to express JAK2WT or JAK2V617F. 
Only JAK2V617F BMT mice developed myelofibrosis-like disease, including 
leukocytosis, splenomegaly, and bone marrow fibrosis (Figure 5-1). They also exhibited 
higher mortality than control or JAK2WT BMT mice. 
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Figure 5-1.  Development of myelofibrosis-like disease in JAK2V617F 
BMT mice. 
BALB/c mice were subjected to BMT with bone marrow donor cells retrovirally 
transduced to express JAK2V617F or JAK2WT. Eighty days after BMT, 
peripheral blood samples and organs were collected. (a) Survival. (b) 
Peripheral blood count. (c) Spleen weight. (d) Spleen sections. Hematoxylin 
and eosin. (e) Bone marrow. Reticulin staining (original magnification ×200). (f) 
Inset from (d), right panel. 
 
We next evaluated the efficacy of NS-018 in this model. When disease was 
established at 10 days after transplantation, JAK2V617F BMT mice were randomly 
assigned to either of two groups for treatment with NS-018 or vehicle. NS-018 was 
administered by oral gavage twice a day for 40 days at a dose of 50 mg/kg, while the 
control group received vehicle only. No signs of gross toxicity were observed during the 
40 days of treatment. 
During the total of 50 days of the study, four of eight mice in the vehicle-treated group 
died, whereas no mice in the NS-018-treated group died (Figure 5-2a). This represents 
a statistically significant prolongation of survival in the NS-018-treated group (P<0.05). 
Vehicle-treated JAK2V617F BMT mice showed marked leukocytosis (Figure 5-2b), as 
evidenced by a 47-fold increase in the mean white blood cell (WBC) count in the 
peripheral blood of vehicle-treated mice to 359 × 109/L (compared to 7.6 × 109/L in 
control mice). NS-018 treatment achieved a 95% suppression of this increase to 17.4 × 
109/L. In vehicle-treated JAK2V617F BMT mice, the differential WBC count showed that 
the neutrophils had increased to 80.0%, compared to 7.5% in control mice (Figure 5-2c). 
Conversely, the percentage of lymphocytes in vehicle-treated JAK2V617F BMT mice 
was 10.7%, compared to 88.8% in control mice. NS-018 treatment partially suppressed 
both the increase in neutrophils and the decrease in lymphocytes, giving 47.9% 
f
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neutrophils and 42.2% lymphocytes. JAK2V617F BMT mice showed a higher 
reticulocyte (RETIC) count than control mice but about the same red blood cell (RBC) 
count. NS-018 treatment did not decrease the RBC and only marginally decreased the 
RETIC count (Figure 5-2d). JAK2V617F BMT mice showed a 78% decrease in the 
platelet (PLT) count compared with control mice (Figure 5-2e), and NS-018 treatment 
did not further decrease the count. 
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Figure 5-2.  Effect of NS-018 on survival and peripheral blood counts in 
JAK2V617F BMT mice. 
(a) Kaplan-Meier plot of untransplanted control mice treated with vehicle 
(Control) and JAK2V617F BMT mice treated with vehicle (Vehicle) or 50 mg/kg 
NS-018 (NS-018) for 40 days. Statistical significance in survival between the 
Vehicle and NS-018 groups was assessed by the log-rank test (*P<0.05, eight 
mice per group). (b) White blood cell (WBC), (c) neutrophil (NEUT) and 
lymphocyte (LYMPH), (d) red blood cell (RBC) and reticulocyte (RETIC) and (e) 
platelet (PLT) counts. Bars represent the mean ± s.e.m. The statistical 
significance of differences between the Control and Vehicle groups (#P<0.05) 
and between the Vehicle and NS-018 groups (*P<0.05) were assessed by the 
Welch test. 
 
Vehicle-treated JAK2V617F BMT mice also showed marked splenomegaly, with 
higher average spleen weights (2.07 ± 0.08 g) than control mice (0.10 ± 0.01 g) (Figure 
5-3a). NS-018-treated JAK2V617F BMT mice had a spleen weight of 0.49 ± 0.08 g, or 
24% of that of vehicle-treated mice, so that NS-018 largely prevented the development 
of splenomegaly. The histopathological results also provide evidence that NS-018 
treatment suppressed the development of splenomegaly. Spleen sections from 
vehicle-treated JAK2V617F BMT mice exhibited complete disruption of the normal 
splenic architecture (Figure 5-3b,c). The white pulp was partially preserved but blended 
throughout, and the red pulp was expanded, mainly by myeloid-cell invasion. NS-018 
treatment resulted in markedly reduced myeloid-cell invasion and a less disrupted 
splenic architecture (Figure 5-3d). 
Finally, NS-018 partially suppressed bone marrow fibrosis in JAK2V617F BMT mice 
(Figure 5-3e–g). There was mild-to-moderate reticulin fibrosis in all vehicle-treated mice 
that survived to the study endpoint (n = 4), whereas in seven of eight mice treated with 
NS-018 there was only slight-to-little reticulin fibrosis. Only one NS-018-treated mouse 
showed mild fibrosis. Taken together, these results show that NS-018 reduced 
leukocytosis and splenomegaly, suppressed bone marrow fibrosis, and prolonged 
survival in JAK2V617F BMT mice without reducing the RBC or PLT counts. 
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Figure 5-3.  Effect of NS-018 on spleen weight and bone marrow fibrosis 
in JAK2V617F BMT mice. 
NS-018 was orally administered for 40 days at 50 mg/kg twice a day. After 
treatment, spleens and femurs were removed. (a) Spleen weight. Bars 
represent the mean ± s.e.m. The statistical significance of differences between 
the Control and Vehicle groups (##P<0.01) and between the Vehicle and 
NS-018 groups (**P<0.01) were assessed by the Welch test. (b–d) Spleen 
sections stained with hematoxylin and eosin (original magnification ×40). (e–g) 
Bone-marrow tissue sections prepared from femur and stained for reticulin 
(original magnification ×200). 
 
 
5-3-2 Preferential inhibition by NS-018 of the growth of cells harboring 
JAK2V617F 
 
Inhibition of JAK2WT can decrease the RBC or PLT counts. To compare the inhibitory 
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effect of NS-018 on JAK2WT and JAK2V617F in cells, we assessed the antiproliferative 
activity of NS-018 against Ba/F3 cells expressing murine JAK2WT or murine 
JAK2V617F. NS-018 suppressed the growth of Ba/F3-JAK2V617F cells with an IC50 
value of 470 nM, while it suppressed the growth of Ba/F3-JAK2WT cells stimulated with 
IL-3 with an IC50 value of 2000 nM (Table 5-1). Thus, NS-018 showed 4.3-fold selectivity 
for Ba/F3-JAK2V617F cells over Ba/F3-JAK2WT cells (V617F/WT ratio). Other JAK2 
inhibitors also showed selectivity for Ba/F3-JAK2V617F over Ba/F3-JAK2WT cells 
(Table 5-1), though the selectivity was lower. For example, INCB018424 (ruxolitinib) and 
TG101348 showed V617F/WT ratios of 2.0 and 1.5, respectively. Thus, among the eight 
JAK2 inhibitors tested, NS-018 showed the highest selectivity for JAK2V617F cells. 
 
Table 5-1.  Antiproliferative activities of NS-018 and other JAK inhibitors in Ba/F3 
cells. 
 
Compound 
Target 
kinase 
Proliferation IC50 (nM) Selectivity 
Interaction with 
Gly993 
Ba/F3-JAK2
WT (+IL-3) 
Ba/F3-JAK2
V617F 
V617F/WT CH···O 
Water-me
diated 
NS-018 
JAK2, 
Src 
2000 470 4.3 Yes Yes 
AZD1480 JAK1/2 2300 1000 2.3 Yes No 
CP-690,550 
(tofacitinib) 
JAK1/2/3 2200 760 2.9 No No 
INCB018424 
(ruxolitinib) 
JAK1/2 630 310 2.0   
CYT387 
(momelotinib) 
JAK1/2 4300 2400 1.8   
TG101209 JAK2 850 550 1.5   
TG101348 
(fedratinib) 
JAK2 1000 650 1.5   
AT9283 
JAK2/3, 
Aurora 
48 48 1.0 No No 
 
To further evaluate the functional selectivity of NS-018 for JAK2V617F cells, we 
performed erythroid colony formation assays with bone-marrow cells from JAK2V617F 
transgenic mice and WT control mice. NS-018 inhibited the formation of erythroid 
colony-forming units from WT control and JAK2V617F transgenic mice in a 
dose-dependent manner, but the degree of inhibition was significantly greater in the 
JAK2V617F transgenic mice (Figure 5-4). Specifically, in JAK2V617F transgenic mice, 
NS-018 inhibited erythroid colony growth with a mean IC50 value of 360 nM, whereas in 
WT control mice the corresponding IC50 value was > 600 nM. These results show that 
NS-018 preferentially suppressed the growth of cells harboring JAK2V617F. 
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Figure 5-4.  Effect of NS-018 on erythroid colony formation in 
JAK2V617F transgenic mice.  
Bone-marrow cells harvested from JAK2V617F transgenic or WT mice were 
treated with increasing concentrations of NS-018 in a methylcellulose-based 
medium containing erythropoietin. Erythroid colony-forming units (CFU-E) were 
counted after incubation for two days. Bars represent the mean ± s.e.m. (n = 4). 
Statistical significance was assessed by a two-way factorial analysis of 
variance (*P<0.001). 
 
5-3-3 Unique mode of binding of NS-018 to (flipped) Gly993 of activated 
JAK2 
 
The JAK2 activation loop, which has a DFG (Asp–Phe–Gly) motif at the start, 
regulates kinase activity by changing its position. The position of Gly993, located 
immediately N-terminal to the DFG motif, thus depends on the activation state of the 
kinase [85]. The X-ray co-crystal structure of JAK2 in complex with NS-018 (Figure 5-5) 
revealed that NS-018 formed hydrogen bonds with the backbone amino and carbonyl 
groups of Leu932 in the hinge region. In addition, NS-018 interacted with the carbonyl 
group of Gly993 through two kinds of hydrogen-bonding interactions. Firstly, there is a 
hydrogen bond between a nitrogen atom of NS-018 and the water molecule depicted by 
the red sphere in Figure 5-5. This hydrogen-bonded water molecule forms a second 
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hydrogen bond with the carbonyl group of Gly993. Thus, there are water-mediated 
hydrogen-bonding interactions between NS-018 and Gly993. Secondly, there is a 
CH•••O hydrogen bond between an aromatic CH on the fluorobenzene moiety of 
NS-018 and the carbonyl group of Gly993 (Figure 5-6a). This type of hydrogen-bonding 
interaction often plays a role in the binding of kinase inhibitors to their target kinases 
[109]. Taken together, NS-018 binds in an induced-fit manner to the activated JAK2 
through two kinds of hydrogen-bonding interactions with Gly993. 
 
 
 
Figure 5-5.  Ribbon-and-stick representation of the X-ray co-crystal 
structure of NS-018 (blue) bound to JAK2 (grey). 
Dashed lines represent hydrogen bonds. 
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Figure 5-6.  X-ray structures of (a) NS-018, (b) AZD1480, (c) CP-690550, 
and (d) AT9283 in complex with JAK2 kinase. 
Protein Data bank IDs for AZD1480, CP-690550, and AT9283 are 2XA4, 3FUP, 
and 2W1I, respectively. 
 
 
5-4 Discussion 
 
In our search for a JAK2 inhibitor with reduced hematologic adverse effects, we 
evaluated the potential of our novel JAK2 inhibitor NS-018 in preclinical models. We first 
assessed the selective inhibition of the mutant kinase JAK2V617F by NS-018 in Ba/F3 
cells. NS-018 showed higher selectivity for JAK2V617F over JAK2WT (a higher 
V617F/WT ratio) than existing JAK2 inhibitors such as ruxolitinib and TG101348 (Table 
5-1). The preferential inhibition of the growth of Ba/F3-JAK2V617F cells by JAK2 
inhibitors was unrelated to their target specificity among Jak-family kinases (e.g., 
selectivity for JAK1/2 or JAK2). 
NS-018 shows potent inhibition of Src-family kinases in addition to JAK2 [108], and it 
could be argued that this contributed to its activity against Ba/F3-JAK2V617F cells. 
a b
c d
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However, Src-family kinases expressed in Ba/F3-JAK2V617F cells were not 
phosphorylated (Figure 5-7) and therefore not activated. Furthermore, the Src-family 
kinase inhibitor dasatinib did not show potent antiproliferative activity against 
Ba/F3-JAK2V617F cells (IC50 = 5000 nM; data not shown). For these reasons, it is 
unlikely that the Src-inhibitory activity of NS-018 contributed to its antiproliferative 
activity against Ba/F3-JAK2V617F cells. 
 
 
 
Figure 5-7.  Phosphorylation status of Src in Ba/F3-JAK2V617F cells. 
Ba/F3-JAK2V617F cells were treated with increasing concentrations of NS-018 
or ruxolitinib for 3 h. Total cell lysate was subjected to SDS-PAGE, transferred 
to a PVDF membrane and probed with antibody specific for phospho-Src family 
(Tyr416) or Src (Cell Signaling Technology). 
 
The efficacy of several JAK2 inhibitors has been evaluated in JAK2V617F BMT model 
mice [110,111], but there are phenotypic differences in disease severity among mouse 
strains [68]. Thus, BMT in BALB/c mice results in more markedly elevated leukocyte 
counts, a greater degree of splenomegaly and reticulin fibrosis, and higher mortality, 
than in C57Bl/6 mice. To assess the effect of NS-018 on bone marrow fibrosis, we used 
the more severely affected strain, BALB/c, to establish a BMT model. Although our 
model mice showed elevated WBC counts, splenomegaly, high mortality, and bone 
marrow fibrosis, as previously reported [68], elevated peripheral RBC and PLT counts 
were not observed (Figure 5-1). Rather, the mice showed thrombopenia 50 days after 
transplantation (Figure 5-2e). Although the reason for the differences in pathologic 
phenotype from the previous report is unclear, possible reasons are the difference in the 
promoters of the retroviral vectors used and the difference in the progenitor cell types 
infected with retrovirus. 
p-SRC
SRC
0     10    30  100  300 1000    0    10    30   100  300 1000 (nM)
NS-018                   Ruxolitinib
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While NS-018 treatment markedly reduced leukocytosis in JAK2V617F BMT model 
mice (Figure 5-2b), it did not decrease the RBC or PLT counts (Figure 5-2d,e). Because 
our BMT model had some unusual features, including the absence of polycythemia and 
thrombocythemia as described above, this apparent lack of effect of NS-018 on the 
RBC and PLT counts should be interpreted carefully. However, it is consistent with our 
previous finding that NS-018 prevents the progression of anemia and the decrease in 
PLT count in JAK2V617F transgenic mice [108]. When we evaluated the another JAK2 
inhibitor, R723, in the same model, prevention of progressive anemia was not observed 
[110]. Because JAK2 signaling plays important roles in erythropoiesis and 
thrombopoiesis [99-101], JAK2 inhibition is thought to have on-target adverse effects 
such as a decrease in the RBC and PLT counts. In fact, some JAK2 inhibitors do reduce 
the RBC or PLT count in mice [110-113]. More importantly, the dose-limiting toxicity of 
ruxolitinib in MPN patients is thrombocytopenia [80,114]. Thus, a JAK2 inhibitor that 
produces a smaller reduction in the RBC and PLT counts in the therapeutic window 
would have clinical benefit. As described here, NS-018 preferentially inhibited the 
growth of Ba/F3-JAK2V617F cells (Table 5-1) and suppressed erythroid colony 
formation from bone marrow cells from JAK2V617F transgenic mice (Figure 5-4). 
Furthermore, NS-018 inhibits erythroid colony formation by peripheral blood 
mononuclear cells from JAK2V617F+ polycythemia vera patients at concentrations 
significantly lower than those required for healthy controls [108]. These results suggest 
that NS-018 inhibits the constitutively active JAK2V617F more potently than wild-type 
JAK2, which is involved in normal erythropoiesis and thrombopoiesis. This preferential 
inhibition of JAK2V617F by NS-018 could explain the fact that NS-018 does not reduce 
the RBC or PLT count at therapeutic doses in mouse models. The concentration range 
over which NS-018 inhibits JAK2V617-dependent cells but not wild-type cells in the 
model mice might be wider than for other JAK2 inhibitors. 
In the present study, NS-018 treatment improved bone marrow fibrosis in JAK2V617F 
BMT mice (Figure 5-3e–g). This contrasts with our previous study of JAK2V617F 
transgenic mice in which NS-018 treatment had little effect on the progression of bone 
marrow fibrosis [108]. However, the fibrosis in the transgenic mice was more severe 
than in the BMT mice used in the present study. In addition, in the transgenic mice 
NS-018 was administered on weekdays only, whereas in the BMT mice it was 
administered every day. The lack of dosing of the transgenic mice over the weekend 
might have reduced the effect of NS-018 on the fibrosis. Some JAK2 inhibitors, 
including TG101348 and CYT387, improve bone marrow fibrosis in JAK2V617F BMT 
mice [110,111], but unfortunately they also produce a decrease in the hematocrit in the 
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therapeutic dose range in mice. Thus, an important and distinctive feature of NS-018 is 
its apparent lack of a suppressive effect on the RBC and PLT counts in the therapeutic 
window in mouse models. 
To investigate the structural factors determining the preference of NS-018 for 
JAK2V617F, we explored the X-ray co-crystal structures of the inhibitors listed in Table 
5-1. As shown in Figure 5-5 and Figure 5-6a, NS-018 interacts with the carbonyl group 
of Gly993, which is located immediately N-terminal to the DFG motif, through two kinds 
of hydrogen-bonding interactions that are only operative in activated JAK2. These 
interactions could explain the high V617F/WT ratio of NS-018. While similar CH•••O 
hydrogen-bonding interactions with Gly993 are found for AZD1480 (Figure 5-6b), the 
water-mediated interaction is absent. This could account for the lower V617F/WT ratio 
of AZD1480 compared with NS-018. CP-690,550 interacts with JAK2 in a unique way 
(Figure 5-6c); specifically, 1) Gly993 does not interact directly with CP-690,550, and 
Asp994 is located close to CP-690,550, and 2) a unique interaction is found between 
the terminal CN group of CP-690,550 and the glycine-rich loop (P-loop) [115]. Although 
the reason for CP-690,550’s relatively high V617F/WT ratio is unclear, a different 
mechanism could contribute to the recognition of the active state of JAK2 by 
CP-690,550. INCB018424 and CYT387 also have the terminal CN group, so a similar 
recognition mechanism might be operative for these compounds. A docking model of 
the interaction of TG101209 with JAK2 has been published [94], but the X-ray structure 
is still unavailable. It was thus impossible to perform detailed analyses for TG101209 
and the structurally similar TG101348. The X-ray structure shows that AT9283 does not 
interact with Gly993 (Figure 5-6d), and accordingly AT9283 showed no preference for 
V617F. A recent study of the JAK2 inhibitor LY2784544, which has a high preference for 
JAK2V617F, also emphasizes the interaction with Gly993 [116]. All these facts point to 
the importance of considering interactions with Gly993 when the aim is to design 
inhibitors with higher V617F/WT ratios. 
In summary, NS-018 preferentially inhibited the growth of JAK2V617F-harboring cells 
over JAK2WT-harboring cells. NS-018 was also effective against leukocytosis, 
splenomegaly, and bone marrow fibrosis, and prolonged survival in JAK2V617F BMT 
mice with no reduction in the RBC or PLT counts. These characteristic features of 
NS-018 may be explained at least in part by its unique mode of binding to the activated 
form of JAK2. This may contribute to a therapeutic benefit for MPN patients by allowing 
the simultaneous satisfaction of the two requirements of efficacy and reduced 
hematologic adverse effects. The efficacy and safety of NS-018 for the treatment of 
MPN is expected to be verified by ongoing clinical trials. 
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Chapter 6 
 
Evaluation of NS-018 in high-risk myelodysplastic 
syndrome patient samples 
 
 
6-1 Introduction 
 
Myelodysplastic syndrome (MDS) is a malignant hematologic disease characterized 
by variable cytopenia due to ineffective hematopoiesis with dysplastic hematopoietic 
cells and an increased risk of evolution to acute myelogenous leukemia (AML), and it is 
highly heterogeneous in that it displays a variety of complex cytogenetic and molecular 
abnormalities [117–120]. Despite recent advances in the understanding of its molecular 
features, the treatment outcome of MDS remains unfavorable. In particular, as reflected 
by the International Prognosis Scoring System (IPSS), revised IPSS (IPSS-R) and 
WHO Prognosis Scoring System (WPSS), the outlook for MDS patients having poor 
prognostic cytogenetic abnormalities and advanced disease stage with an increased 
percentage of abnormal myeloblasts in the bone marrow (BM) and/or peripheral blood is 
extremely unfavorable [121–124]. Although allogeneic hematopoietic stem cell 
transplantation (allo-SCT) is a curative treatment approach [125], it can be applied only 
to younger MDS patients, and its success is limited by the high rate of relapse in 
patients with high-risk cytogenetics [126]. Conventional combination chemotherapies, 
including cytarabine and/or anthracyclines, potently induce remission in a proportion of 
MDS patients by suppressing MDS clones; however, the treatment outcome is 
frequently hampered by high rates of relapse, delayed recovery of normal 
hematopoiesis, and related complications such as infection [127,128]. Pharmacologic 
intervention with novel epigenetic modifiers such as azacitidine (5-Aza) has induced 
more durable remission in MDS patients compared with conventional cytotoxic 
therapies or best supportive care; however, 5-Aza induced hematologic complete 
remission in only 20–30% of patients and rarely cured MDS [129]. Therefore, the 
development of additional therapeutics which can effectively suppress MDS clones with 
 80 
 
less toxicity against normal hematopoiesis is urgently needed for the treatment of MDS, 
especially in high-risk patients. 
  Normal hematopoiesis requires the fine tuning of cell signaling networks which 
regulate hematopoietic stem cell maintenance, survival and differentiation. For instance, 
activation of the Janus kinase/Signal transducers and activators of transcription 
(JAK/STAT) pathway promotes hematopoiesis in response to the binding of cytokines 
such as stem cell factor, granulocyte-colony stimulating factor, erythropoietin, 
interleukin-3 or thrombopoietin to their respective receptors, while it also induces 
negative feedback regulators such as SOCS (suppressor of cytokine signaling) or CIS 
(cytokine-induced STAT inhibitor) family proteins, which silence positive signals to 
prevent excessive hematopoiesis [130]. The disharmony of the positive and negative 
signaling is involved in the pathophysiology of hematologic malignancies. In chronic 
myelogenous leukemia with aberrant constitutively active Abl tyrosine kinase, 
abnormally upregulated downstream cell-proliferation signals, including those mediated 
by the JAK/STAT, RAS/MAPK and AKT pathways, override the inhibitory signals despite 
the over-expression of SOCS-family members [131,132]. Somatic mutations in the 
JAK2 gene which cause constitutive activation of STATs are involved in the 
pathogenesis of myeloproliferative neoplasms (MPNs) and refractory anemia with 
ringed sideroblasts with thrombocytosis, a subtype of MDS/MPN [66,133]. Insufficient 
inactivation of the JAK/STAT pathway due to the repression of SOCS-1 or SHP-1 
through gene hypermethylation is involved in the progression of high-risk MDS and AML 
[134,135]. These findings prompted us to investigate whether JAK2 inhibition can 
selectively inhibit the proliferation of MDS clones, especially those with a high potency 
for clonogenic proliferation. To test this hypothesis, we investigated the effect of a novel 
highly selective JAK2 inhibitor, NS-018, which is under early phase clinical trial for MPN, 
on the colony-forming ability and STAT3 phosphorylation status of hematopoietic 
progenitor cells from high-risk de novo MDS patients. 
 
 
6-2 Materials and Methods 
 
6-2-1 Cells, reagents and colony formation assay 
 
This study was approved by the institutional review boards of Kyoto Prefectural 
University of Medicine and Kyoto Second Red Cross Hospital. BM mononuclear cells 
(BMMNCs) from twelve MDS patients and three healthy volunteers were collected with 
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informed consent in accordance with the Declaration of Helsinki. To investigate the 
effect of NS-018 on BMMNCs of highly aggressive MDS, we selected MDS patients 
evaluated as high or very high risk at least by IPSS-R or WPSS at their diagnosis at our 
institute during the past three years, and 12 samples were available for this study. MDS 
subtypes of 12 patients included 2 refractory cytopenia with multilineage dysplasia 
(RCMD), 4 refractory anemia with excess blasts (RAEB)-1, 5 RAEB-2 and 1 
MDS-unclassifiable according to the WHO classification [136]. All MDS patients had 
complex and/or unfavorable cytogenetic abnormalities, and their prognostic risks were 
defined to be intermediate (n = 1), high (n = 2) or very high(n = 9) in the IPSS-R (Table 
6-1) [121–124]. 
NS-018, is an ATP-competitive small-molecule inhibitor of JAK2. The crystal structure 
of NS-018 bound to the JAK2 kinase domain and the in vitro selective inhibitory activity 
of NS-018 against JAK2 kinase has been described elsewhere [108,137]. BMMNCs 
from healthy volunteers and MDS patients were isolated by conventional Ficoll-Paque 
density gradient centrifugation, and the isolated BMMNCs were incubated in MethoCult 
GF H4434 methylcellulose medium containing various hematopoietic cytokines 
(STEMCELL Technologies, Vancouver, Canada) at 1.0 x 105 cells/ml with or without 
NS-018 at 37◦C in a humidified atmosphere of 5% CO2. Commercially available purified 
normal human CD34-positive (CD34+) BM cells (Lonza, Walkersville, MD) were used as 
a control. Burst-forming unit-erythroid (BFU-E) and colony-forming 
unit-granulocyte/macrophage (CFU-GM) colonies were counted under an inverted 
microscope on day 14 of culture. 
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Table 6-1.  Clinical and cytogenetic/epigenetic features of MDS patients. 
 
 
 
M, male; F, female; RAEB, refractory anemia with excess blasts; RCMD, 
refractory cytopenia with multilineage dysplasia; MDS-U, MDS-unclassifiable; 
NCC, nucleated cell count; BM, bone marrow; PB, peripheral blood; IPSS, 
International Prognostic Scoring System; IPSS-R, Revised IPSS; WPSS, WHO 
Prognostic Scoring System; Int, intermediate; H, high; VH, very high; HC, 
hydroxycarbonate; BSC, best supportive care; 5-Aza, 5-azacitidine; R-BMT, 
related bone marrow transplantation; UR-BMT, unrelated bone marrow 
transplantation; CTx, chemotherapy with cytotoxic agents; Len, lenalidomide; 
LBH-589, panobinostat. N.A., not available, N.E., not examined. 
 
 
Age 
/Gender 
WHO 
MDS 
subtype 
NCC 
(x10
9
/L) 
BM 
Blast 
(%) 
PB 
Blast 
(%) 
chromosome 
IPSS 
IPSS-R 
WPSS 
Methylation JAK2 
mutation 
Treatment Prognosis 
SOCS-1 SHIP1 
1 57/M RAEB-1 77.0 4.8 2 
46, XY, del(7)(q11.2) [6] / 46, sl, 
del(12)(p?), +14, der(14;18)(q10;q10) [8] / 
46, sl, del(7), +der(7)del(7)(p?)del(7) [6] 
Int-1 
VH 
VH 
+ ++ - 
Metenolone 
HC 
32M 
2 84/F RAEB-2 25.0 14 3 
47, XX, +8 [15] / 48, idem, +8 [1] / 46, XX 
[4] 
H 
VH 
VH 
++ ++ - BSC 3M+ 
3 54/M RCMD 821.0 4.4 0 
46, XY, i(17)(q10) [19] / 46, idem, 
del(2)(q?) [1] 
Int-1 
H 
Int 
- ++ - 
5-Aza 
R-BMT 
10M+ 
4 61/F RAEB-1 46.0 5.4 0 
45, XX, del(5)(q?), -9, add(21)(p11.2), 
add(22)(q11.2) [6] / 46, idem, +mar1 [10] / 
46,XX [3] 
Int-2 
VH 
VH 
++ + - 
CTx 
UR-BMT 
17M+ 
5 70/M RAEB-1 189.0 3.2 2 
44, XY, dic(5;12)(q11.2;p11.2), -7, 
add(7)(q11.2), -22, +mar1 [5] / 44, idem, 
add(3)(p11) [2] / 43, idem, add(3)(p11), 
-mar1 [6] / 46, XY [7] 
Int-2 
VH 
VH 
- + - 5-Aza 10M 
6 80/M RCMD 184.0 3.8 0 
46, XY, add(5)(q11.2) [1] / 45, sl, 
del(1)(p?), -7, -10, add(11)(q23), -13, 
-15, add(19)(p13), +rl, +mar1, +mar2 [6] 
/ 45, sl, -18, -20, +r2 [2] / 46, XY [1] 
H 
VH 
H 
N.A. N.A. N.A. BSC 7M+ 
7 67/M RAEB-2 203.0 10.2 3 
45, XX, add(4)(q21), der(5;19)(p10;q10), 
del(7)(q?), -9, +19, add(21)(q22) [1]/ 45, 
idem, -add(4), +rl [3]/ 46, XX, der(5;19), 
der(7;12)(p10;q10), +8, +19 [1] 
H 
VH 
VH 
  N.A. 5-Aza 9M 
 
8 63/F RAEB-2 96.0 14.4 9 
46, XX, add(6)(p21) [3]/ 46, XX, 
del(7)(q?) [3]/ 46, XX, del(12)(p11.2) 
[1]/ 46, XX, t(21;22)(q22;q11.2) [1]/ 46, 
XX [8] 
Int-2 
VH 
VH 
  N.A. 
CTx 
UR-BMT 
5-Aza+Len 
10M+ 
9 86/M RAEB-2 154.0 10.1 1 46, XY, t(3;3)(q21;q26.2) [20] 
Int-2 
VH 
VH 
  N.A. Metenolone 20M+ 
10 72/M RAEB-2 165.0 11.6 8 47, XY, +8 
Int-2 
H 
H 
  N.A. 
5-Aza 
+LBH-589 
16M+ 
11 72/M RAEB-1 25.0 6.4 3 
46, XY, +1, der(1;7)(q10;p10) [6]/ 46, 
idem, inv(7)(q11.2q36) [5]/ 45, X, -Y [3]/  
46, XY [5] 
H 
VH 
VH 
  N.A. 5-Aza 4M 
12 68/M MDS-U 51.0 3.4 0 
46, XY, +1, der(1;7)(q10;p10) [18]/ 46, 
XY [2] 
Int-2 
Int 
H 
  N.A. 5-Aza 12M+ 
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6-2-2 Western blotting 
 
After the evaluation of colony numbers on day 14 of culture, colony-forming cells were 
collected, washed twice with phosphate buffered saline (PBS) (−) and resuspended in 
RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamate and 
penicillin/streptomycin. Cells were cultured for 3 h with or without 1 μM NS-018 and then 
lysed. Western blotting was performed as described elsewhere [138]. Briefly, protein 
samples were separated by SDS-PAGE and then electroblotted onto a Hybond-P PDVF 
membrane (Amersham Biosciences, Uppsala, Sweden). The membranes were blocked 
with 5% (w/v) non-fat dry milk in PBS containing 0.1% (v/v) Tween 20 (Sigma, St Louis, 
MO). Antibodies (Abs) against STAT3 (Cell Signaling Technology, Beverly, MA), 
α-tubulin (Sigma) and phosphorylated (phospho-) STAT3 (Cell Signaling Technology) 
were used. Abs were detected by using horseradish peroxidase-conjugated secondary 
Abs and the enhanced chemi-luminescence (ECL) or ECL Prime Western Blotting 
Detection System (Amersham Biosciences). 
 
6-2-3 Detection of genetic abnormalities in BMMNCs from MDS patients 
 
We investigated the methylation status of the SOCS-1 and SHP-1 genes and the 
JAK2 gene mutation JAK2V617F in MDS-BMMNCs analyzed in this study. For the 
qualitative detection of methylated cytosine bases in the SOCS-1 and SHP-1 genes, 
regardless of the methylation level, conventional bisulfite pretreatment and 
methylation-specific polymerase chain reaction (PCR) was performed as described by 
[134,135,139]. The JAK2V617F gene mutation was analyzed by using the ipsogen 
JAK2 MutaScreen Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. Briefly, this kit enables the identification of the JAK2V617F gene mutation 
by a multiplex assay using two TaqMan probes, of which one is specific for the wild-type 
JAK2 gene and the other for the JAK2V617F gene mutation. 
 
6-2-4 Statistical analysis 
 
All data were analyzed with two-sided, unpaired t-tests, and a P value of 0.05 was 
considered significant. Values are expressed as the mean ± SD of independent 
colony-forming assays conducted in triplicate. 
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6-3 Results 
 
6-3-1 Formation of CFU-GM and BFU-E colonies from MDS-derived 
BMMNCs 
 
First, we examined the colony-forming ability of normal and MDS-derived BMMNCs 
(MDS-BMMNCs) in MethoCult medium. The ability of purified CD34+ cells to produce 
hematopoietic colonies was more than 10-fold that of unpurified normal BMM-NCs. Two 
of twelve MDS-BMMNCs failed to form hematopoietic colonies, and, even in the ten 
MDS-BMMNCs which did form hematopoietic colonies, there were significantly fewer 
colonies than when purified CD34+ cells were used (P < 0.001), and they were fewer 
than when unpurified normal BMMNCs were used (P = 0.007). Two of two samples of 
purified normal CD34+ cells and all three normal BMMNC samples produced 
hematopoietic colonies with almost equal frequencies for BFU-E and CFU-GM, while in 
MDS-BMMNC-derived colonies the majority of hematopoietic colonies were CFU-GM 
(Table 6-2). 
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Table 6-2.  Colony formation by CD34+ bone-marrow mononuclear cells 
(BMMNCs), BMMNCs from healthy donors and MDS patients. 
 
 
Cells (1 x 105 cells/ml) were incubated in MethoCult and the numbers of 
burst-forming unit-erythroid (BFU-E) and colony-forming 
unit-granulocyte/macrophage (CFU-GM) colonies were counted after 14 days. 
N.A.: not applicable. 
 
  
    
BFU-E 
(colony count) 
CFU-GM 
(colony count) 
CFU-GM  
ratio (%) 
CD34
+ 
BM 
1 4400  5700  56.4  
2 6200  4900  44.1  
Mean ± SD 5300 ± 1273 5300 ± 566 50 
Control 
1 200  220  52.4  
2 433  468  51.9  
3 543  688  55.9  
Mean ± SD 433 ± 175 468 ± 234 52  
MDS 
1 4  27  87.1  
2 0  0  NA 
3 1  162  99.1  
4 3  9  78.3  
5 9  144  94.3  
6 0  0  NA 
7 11 279 96.2 
8 26 321 92.5 
9 4 179 97.8 
10 47 394 89.3 
11 18 29 61.7 
12 16 60 78.9 
Mean ± SD 11.6 ± 13.8 133.7 ± 136.8 87.5  
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6-3-2 Methylation status of SOCS-1 and SHP-1 genes and JAK2 gene 
mutation status of MDS-derived MDS-BMMNCs 
 
We examined the methylation status of the SOCS-1 and SHP-1 genes of 
MDS-BMMNCs. Genomic DNA samples from eleven of twelve patients were available 
(the exception was patient 6). Although the degree of methylation differed among the 
samples, the methylated SOCS-1 gene was detected in four of eleven MDS-BMMNC 
samples and the methylated SHP-1 gene was detected in seven of eleven 
MDS-BMMNC samples examined (Figure 6-1A and Table 6-1). No JAK2V617F gene 
mutation was identified in any of five samples examined (Figure 6-1B). 
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Figure 6-1.  Genetic features of MDS patients. 
(A) Methylation status of SOCS-1 andSHP-1 genes in bone-marrow 
mononuclear cells from MDS patients. M, methylated; U, unmethylated. Pt, 
patient. (B) JAK2V617F gene mutation status in bone-marrow mononuclear 
cells from MDS patients. Data of Pts. 1 to 5 are representative of eleven 
patients except for Pt. 6. The Y-axis represents the mean ± SD of the relative 
fluorescence ratio between mutated and wild type JAK2 genes in the positive 
control for the mutated JAK2 gene (P), the negative control with the wild type 
JAK2 gene supplied in the kit, and genes from Pts. 1 to 5. 
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6-3-3 NS-018 preferentially suppresses CFU-GM formation from 
MDS-derived BMMNCs 
 
To investigate whether targeting JAK2 activity has therapeutic potential for MDS, we 
examined the effect of NS-018 on the colony-forming ability of unpurified BMMNCs from 
healthy controls and MDS-BMMNCs. NS-018 suppressed the CFU-GM colony 
formation of both normal BMMNCs and MDS-BMMNCS in a dose-dependent manner. 
Specifically, 0.5 μM NS-018 decreased the numbers of CFU-GM colonies from normal 
BMMNCs and MDS-BMMNCs to 87.2 ± 8.2% and 45.8 ± 8.8% (P < 0.001), respectively, 
and the corresponding figures for 1.0 μM NS-018 were 61.4 ± 18.6% and 25.1 ± 11.5% 
(P = 0.0015), respectively, compared to untreated MNCs (Figure 6-2A and 6-2B). This 
result demonstrates that NS-018 preferentially suppressed CFU-GM formation from 
MDS-BMMNCs over that of normal BMMNCs. 
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Figure 6-2.  Effect of NS-018 on CFU-GM formation by bone-marrow 
mononuclear cells (BMMNCs) from healthy donors and MDS patients. 
(A) Cells (1 × 10 5 cells/ml) were incubated in MethoCult with or without NS-018 
at 0.5 or 1.0 μM and the numbers of colony-forming 
unit-granulocyte/macrophage (CFU-GM) colonies were counted after14 days. 
The left panel shows the results in normal BMMNCs (Control; Ctl.) (n = 3), and 
the right panel shows the results in MDS-BMMNCs (n = 10). No colony 
formation was observed in patients (Pts) 2 or 6. (B) Effect of NS-018 on 
CFU-GM formation between by normal BMMNCs from three healthy volunteers 
and MDS-derived BMMNCs from ten patients (Pts 1–12, except Pts 2 and 6). 
*P < 0.01. 
 
6-3-4  Effect of NS-018 on STAT3 activity of colony-forming BMMNCs 
 
To test whether NS-018 effectively inhibits JAK2 kinase activity in BMMNCs, we 
investigated the phosphorylation status ofSTAT3 before and after NS-018 treatment. 
STAT3 is one of the major target located downstream of JAK2, and it is activated 
through phosphorylation. Basal STAT3 expression levels were higher in CFU-GM 
forming cells from one MDS patient (Pt. 5) than in CFU-GM-forming cells from a normal 
control (Ctl. 3) (Figure 6-3). However, STAT3 was phosphorylated only in 
CFU-GM-forming cells from MDS patients and not in normal BMMNCs, and treatment 
with 1.0 μM NS-018 for 3 h almost completely suppressed the phosphorylation of STAT3 
in CFU-GM-forming cells from MDS patients (Figure 6-3). 
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Figure 6-3.  Effect of NS-018 on STAT3 activity. 
Colony-forming cells from normal and MDS bone-marrow mononuclear cells 
were cultured with or without 1 μM NS-018 for 3 h, and the levels of total STAT3 
and phosphorylated (p-) STAT3 were examined. α-Tubulin was also examined 
as the internal control. Image Lab software (Ver.4.1) (Bio-Rad Laboratories, 
Hercules, CA) was used for the quantification of protein expression levels. The 
expression levels of total STAT3 and p-STAT3 in untreated control cells were 
taken to be 1.0. 
 
 
6-4 Discussion 
 
MDS has two major clinical manifestations, cytopenias and leukemic evolution, and it 
remains a hard-to-treat disease, especially when allo-SCT is not applicable. 
Pharmacologic intervention with immunosuppressants, such as cyclosporine A, and 
anabolic steroids is occasionally efficacious for relatively long-term hematopoietic 
recovery in MDS patients with the major clinical presentation of cytopenias in the 
absence of blast expansion [140,141], whereas no promising treatment exists once the 
disease evolves into the aggressive phase with the excess of blasts that results from the 
acquisition of cell-proliferation potency. Even 5-Aza, the first-line pharmacologic 
intervention at the time of writing, has only a transient effect and rarely cures MDS [129]. 
Although recent genome-wide studies have demonstrated the involvement of various 
types of genetic and epigenetic abnormalities in cell differentiation, cell proliferation, cell 
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survival and RNA splicing during the development and progression of MDS [142,143], 
no single mutation or promising molecular target which is universally critical for MDS 
patients has been identified so far. Therefore, there is an urgent need for a therapeutic 
agent which can suppress the growth of highly proliferative MDS clones in a wide 
variety of patients. 
 Through the analysis of MDS-BMMNCs from high-risk MDS patients with unfavorable 
karyotypes, this study shows that MDS-BMMNCs from the majority (though not all) MDS 
patients produced hematopoietic colonies with a lower frequency than did normal 
BMMNCs. The lower colony-forming ability of MDS-BMMNCs from these patients may 
reflect the susceptibility of MDS clones to apoptosis, which may be associated with 
ineffective hematopoiesis. On the other hand, the ability of MDS-BMMNCs from the 
other patients to form colonies may reflect a more proliferative and highly aggressive 
phenotype of MDS clones, which may cause the excess of blasts clinically [144]. Our 
study demonstrates that the inhibition of the kinase activity of JAK2 preferentially 
suppresses the clonogenic growth of MDS-BMMNCs compared with normal BMMNCs, 
suggesting that JAK2 inhibition is specifically effective in preventing the overgrowth of 
leukemogenic clones in MDS, while it preserves more normal hematopoietic progenitor 
cells than MDS progenitors. A previous study has also shown the anti-cancer activity of 
erlotinib, an inhibitor of epidermal growth factor receptor, against leukemic and MDS 
cells through its off-target inhibitory effects on JAK2 and nucleophosmin [145]. NS-018 
is highly selective for JAK2 [108], and this study is the first to present evidence for the 
effect of the specific inhibition of JAK2 by NS-018 on the clonogenic growth of 
MDS-BMMNCs from high-risk MDS patients. In BMMNCs from patient 5, STAT3 was 
activated even though these cells had no methylated SOCS-1, weakly methylated 
SHP-1 and no JAK2V617F gene mutation. This suggests that the hypermethylation of 
the SOCS-1 and SHP-1 genes and the presence of the JAK2V617F gene mutation, 
which all cause JAK2 activation, are not a prerequisite for the activation of JAK2/STAT 
signaling. Therefore, JAK2 could be universally targetable in MDS with a proliferative 
phenotype regardless of the types of genetic or epigenetic aberration, and NS-018 is a 
candidate agent for aggressive MDS with proliferative phenotype. Nevertheless, 
previous clinical trials have shown that myelosuppression was one of the most frequent 
adverse events with JAK2 inhibitors, such as CEP-701 or INCB018424, in MPNs 
[80,104,146]. Despite the encouraging results from our in vitro study, the extensive 
caution should be needed for myelosuppression in the use of JAK2 inhibitor for MDS 
patients with ineffective hematopoiesis. 
 In conclusion, our results provide the first evidence that a JAK2 inhibitor, NS-018, 
 92 
 
potently suppresses the formation of MDS-BMMNCs with relatively low toxicity against 
normal BMMNCs. NS-018 could be a new therapeutic option for high-risk MDS. 
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Chapter 7 
 
Conclusion 
 
 
Although researchers and medical personnel have high expectations for molecularly 
targeted anticancer drugs, only a few such drugs have been successful. Although the 
concept of molecularly targeted anticancer drugs is precise and essentially correct, the 
techniques used to evaluate them are not precise enough. In other words, there are 
defects in the current strategy of drug discovery. The drug discovery process itself is still 
incomplete and has many challenges. Although high-throughput screening (HTS) using 
cells is a great technique, it is only the first step in selecting compounds. The 
phenotypes of the mutated cells are not identical to that of the disease in human 
patients. It is critical to use an evaluation system in which the healing process is 
identical to that in patients. At present, only an appropriate disease model in animals 
can realize such an evaluation system; it is not currently possible with cells. The current 
strategy of drug discovery has not taken full advantage of animal models. 
To address this problem, I incorporated appropriate animal models into the drug 
discovery process (Figure 7-1). I constructed animal models that accurately reflect the 
patient pathology in two types of hematological malignancies, imatinib-resistant CML 
and MPN, that could not be reproduced in conventional models. The site of action of the 
drug in these models was the bone marrow, which was the location of the original 
cancer. There is a high expectation that drugs which can improve the pathology in these 
model animals can improve the clinical condition of patients. As a result of the improved 
screening of tyrosine kinase inhibitors using these animal models, it was possible to 
increase the probability of selecting promising compounds. The selected compounds, 
NS-187 and NS-018, are in clinical trial for the treatment of CML and MPN, respectively. 
In contrast to the imatinib-resistant CML and MPN, a suitable animal model has not 
been constructed for MDS, although the effectiveness of NS-018 was demonstrated in 
patient cells. Neither NS-018 nor any other JAK2 inhibitors have reached clinical trial in 
MDS. This suggests that evaluation in an appropriate disease model animal is important 
for validation of compounds in the drug discovery process. Although the construction of 
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appropriate disease model animals rarely attracts attention, it is possible to increase the 
success rate of drug discovery by strengthening this part of the process. 
 
 
 
Figure 7-1.  Drug discovery process for tyrosine kinase inhibitors in this 
thesis. 
Ba/F3 transplant mice is a disease model of imatinib-resistant CML. Transgenic 
mice and bone marrow transplantation (BMT) mice are disease models of MPN. 
NS-187 and NS-018 are the compounds selected by screening in the projects. 
 
It is still unclear whether tyrosine kinase inhibitors, including NS-187 and NS-018, can 
truly eradicate cancer. Long-term administration of tyrosine kinase inhibitors will stop 
relapse at least in certain types of cancer. However, tyrosine kinases are obviously not 
almighty as target molecules: their inhibition is not a sufficient therapy for all types of 
cancer. The oncogene addiction hypothesis, which provides a rationale for the current 
strategy, may apply to only specific cancers. Whether or not ideal target molecules 
really exist is a key question facing researchers. They may not be found in the current 
approaches. As mentioned in chapter 1, research on cancer has a long history and 
many concepts and theories have been proposed over the years. New concepts have 
been created in association with technological developments in fields such as autopsy, 
microscopy, chemistry, and genetics. I expect that new technologies and concepts will 
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lead to the development of new approaches and strategies to find ideal target molecules. 
I also believe that we can find ideal compounds as drug candidates if we use suitable 
techniques, including appropriate model animals. 
To conclude, appropriate disease model animals for drug discovery of tyrosine kinase 
inhibitors have been successfully developed, and promising compounds for clinical trials 
have been selected. The probability of selecting promising drug candidates can be 
increased by evaluating compounds in appropriate animal models during the drug 
discovery process. 
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